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Abstract 
This dissertation study examined the relationship of glucose control with clinical 
outcomes, costs, discharge planning and education. Extant studies showed that 
hyperglycemia, in the presence or absence of a diabetes diagnosis, is prevalent in 
hospitalized patients. Hyperglycemia is found in one-third of all hospital admissions and is 
linked to poor clinical outcomes and increased healthcare costs. Furthermore, clinical 
evidence suggests that lack of discharge coordination associated with medical errors and 
readmission. This entire body of work contains three distinct sections: Two manuscripts 
and a grant proposal. The two manuscripts in this study were based on more current 
retrospective data at the time of the study. The first manuscript "Inpatient glycemic 
management: relationship among glucose control, clinical outcomes and costs" discussed the 
results on glucose control, clinical outcomes and costs by provider groups. The second 
manuscript "Inpatientglycemic management: team approach in diabetes education and 
discharge planning" discussed the outcomes of improved discharge planning and 
coordination with the intervention of the glycemic management team. The grant proposal 
"Inpatient glycemic management: clinical and economic impact of changing from sliding scale 
insulin to basal-bolus" was awarded $105,000 funding by a private pharmaceutical 
company. The study associated with the grant funding was a completely separate study 
done in collaboration with the grantor. 
Dedication 
This work is dedicated to my patients and many of my family members who battle 
with diabetes management everyday. Their daily struggles, including momentary lapses or 
dedicated resolve in diabetes care, minor or catastrophic health failures, and every small or 
transformational accomplishments inspire and motivate me in my work to strive for the 
best diabetes care possible for each and every one of them. Diabetes is a disease of the most 
human and humbling kind. Its complications are devastating to the people and their loved 
ones affected by the disease. Despite its grim outcomes, hope exists when individuals 
decide to take steps in healthy lifestyle changes and when we as healthcare providers 
deliver the right guidance and care. With continued collaboration of patients and 
healthcare providers, we can overcome the negative effects of this disease and improve our 
patients' chances in living longer, healthier, and more fulfilled lives. 
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Diabetes is not just a U.S. national health crisis but also a worldwide epidemic. In 
2010, there were 285 million people worldwide affected by diabetes. The North American 
Continent (NAC) has 37 million people with diabetes. This is roughly 10% of the population 
of NAC with a death toll of 16%. Diabetes is the leading cause of neuropathy, nephropathy, 
retinopathy, and coronary artery diseases (IDF, 2009, 2010). Diabetes puts a heavy toll on 
the American people. In the U.S. alone, there are 25.8 million people with diabetes. This is 
8.3% of the total U.S. population and the 6th leading cause of death (CDC, 2011). The overall 
annual cost for care is a staggering $174 billion. Hospital costs of care accounts for $87 
billion or half of the annual cost. Hospital admissions for people with diabetes is prevalent, 
accounting for 7.7 million hospital admissions or one out of every five hospital admissions. 
Patients with diabetes also trigger more emergency department visits, have longer lengths 
of stay, and higher cost of care than patients without diabetes (ADA, 2008). 
Poor glycemic control in the hospital setting can lead to deleterious clinical 
outcomes and increased economic costs. That is why glycemic control is widely recognized 
as an integral part of inpatient care. Glycemic management of hospitalized patients, 
however, is complex and requires considerable hospital resources. Wide glucose variability, 
persistent hyperglycemia, recurrent, and severe hypoglycemia are implicated in poor 
outcomes (Krinsley, 2003, 2008; Krinsley & Grover, 2007). Evidence suggests that 
hyperglycemia during acute illness is a marker of poor clinical outcomes that lead to 
increased morbidity, mortality, and length of stay (Krinsley, 2004; Umpierrez et al., 2002). 
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When blood glucose (BG) is intensively controlled to near normal BG levels of 
approximately less than 140 mg/dl, it reduces the risks of multi-organ failure, sepsis, 
morbidity, mortality, and length of stay (Krinsley & Grissler, 2005; Van den Berghe et al., 
2001). 
Patients with diabetes occupy approximately 12% to 25% of all hospital beds (Cook, 
et al., 2009; Moghissi, 2004). This rate will continue to rise as the incidence of diabetes 
increases nationwide. Hospital organizations and healthcare agencies recognize that 
optimum glycemic control not only improves patient outcomes, it also reduces hospital 
costs. In an effort to improve outcomes, hospital institutions nationwide implemented 
programs to improve inpatient glycemic control. Glycemic targets for critical care units are 
mean BG levels of 140 - 180 mg/dl and less than 140 mg/dl for acute care. The American 
Diabetes Association (ADA) and the American College of Clinical Endocrinologists (AACE) 
recommended these targets with a caveat - achieve euglycemia, control hyperglycemia but 
limit the possible deleterious consequences of severe hypoglycemia (ADA, 2010; Moghissi, 
et al., 2009). 
Inpatient glycemic management is complicated because there are many factors that 
affect blood glucose control (Smith et al., 2005). Hospital organizations nationwide were 
quick to adopt various forms of insulin protocols with mixed successes and failures. The 
increased use of insulin in the hospital setting brought new challenges for clinicians and 
healthcare providers regarding patient safety issues. Insulin is the number one drug 
implicated in medication errors causing harm, according to the MEDMARX® data report (a 
national reporting program for medication errors and adverse drug reactions submitted by 
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participating hospital facilities) published by the United States Pharmacopoeia (Hicks, 
Becker, & Cousins, 2008). The AACE and ADA recognized that hospital systems might 
require administrative support and inpatient glycemic expert providers to successfully 
monitor patient safety and manage care (Moghissi, 2004; Moghissi, et al., 2009). Some 
studies demonstrated that a diabetes team approach to hospital glycemic management and 
transition to ambulatory care were effective in controlling inpatient blood glucose, 
improving post discharge A1C levels, and decreasing length of stay (Flanagan et al., 2008; 
Jakoby et al., 2008) 
Additionally, hospital organizations recognize that in the current healthcare 
environment, physicians do not have the time or the perceived expertise to manage the 
intricate daily issues related to glycemic care (Smith et al., 2005). Many hospitals turned to 
specialized glycemic management teams (GMT) to address inpatient glucose management. 
Many of these GMTs are staffed with a team of healthcare professionals, which include, but 
are not limited to, any or all of these team members: physicians, advanced practice nurses, 
diabetes nurse educators, pharmacists, and/or dietitians (Jakoby et al., 2008; Flanagan, et 
al., 2008). 
The current national economic situation and lack of access to physicians in rural 
areas are some of the reasons for the increased presence of nurse practitioners (NPs) in 
various outpatient and inpatient settings. Although there are some practice differences 
between physicians and NPs, in a study conducted by Mundinger and associates (2000), 
NPs performing at the same authority and responsibility as physicians, had comparable 
patient outcomes. 
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In the last decade, various approaches to achieving glycemic control have been 
established at several institutions in the U.S. and abroad. Despite these efforts, glycemic 
control remains suboptimal (Boord et al., 2009). While there is empirical support for the 
benefits of intensive inpatient glucose management, there is limited research on its 
economic costs or savings in relation to clinical outcomes. Moreover, there is less scientific 
evidence on the impact of GMTs in the care of patients with BG abnormalities who have 
complex and extensive healthcare needs. 
Research Aims 
Hospitals have allocated considerable resources for inpatient glycemic management 
with the use of a dedicated GMT. This retrospective research study is designed to 
determine if there are significant differences in the characteristics of a sample of patients 
receiving traditional care under a physician alone versus GMT (Also see Table 7). Study 
aims include: 
1. Characterize the study population (i.e., age, gender, ethnicity, admission diagnosis, 
admission BG, A1C level, BMI, co-morbid conditions) by type of care delivery. 
2. Examine the differences in glycemic control: mean BG, good glucose control (BG 71 
- 180 mg/dl), incidences of mild to moderate hyperglycemia (BG 181-299 mg/dl), 
severe hyperglycemia BG >300 mg/dl), mild to moderate hypoglycemia (BG 41-<60 
mg/dl), and severe hypoglycemia (<40 mg/dl), by type of care delivery. 
3. Examine which glycemic control variables predict rates of clinical outcomes 
(hospital complications, LOS, inpatient mortality, and 30-day readmission). 
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4. Assess the relationship of glycemic control variables with economic costs (overall 
hospital costs and direct costs). 
5. Examine the differences in inpatient diabetes services provided by type of care 
delivery. 
Conceptual Framework 
The conceptual framework for this study is based upon concepts derived from the 
literature. See figure 1. Inpatient glycemic management has been traditionally the 
attending physician's responsibility. Healthcare practices changed over the last few 
decades resulting in more complex inpatient management and increased healthcare 
provider responsibility. The mounting evidence of the benefits of improved glycemic 
control added another layer of responsibility to an already demanding physician schedule. 
Hence, GMT was implemented to provide assistance to physicians in improving glycemic 
control for hospitalized patients with diabetes or hyperglycemia. 
The main assumption of this study is that the GMT-managed patients, despite having 
more co-morbid conditions, will have improved glycemic control, decreased in-hospital 
complications, and decreased costs compared to patients managed alone by the physician. 
Hence, this study will focus on the differences in the clinical outcomes and economic costs 
between the two provider groups, as well as determine if there is a relationship between 
the ranges of glucose control predictor variables with various clinical and economic 
outcomes (See Figure 1). 
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Figure 1. Conceptual Model 
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CHAPTER 2: REVIEW OF LITERATURE 
There are countless research studies in inpatient hyperglycemia, hypoglycemia, and 
glucose management, especially in the first decade of the 21st century. Scientific research 
interest in inpatient glycemic control has been escalating across the globe. Since the 
general topic of hospital glycemic control is extensive, a methodical effort was made to 
present only a synopsis of the most pertinent diabetes care research studies in relation to 
this research study. The contents of this chapter are organized into ten sections. 
1. Introduction: provides a brief overview and statistical facts about inpatient diabetes. 
2. Critical care setting: reviews landmark studies that may have broadened research in 
inpatient hyperglycemia and its management. 
3. Surgical care setting: discusses the role of hyperglycemia in surgical patients. 
4. General hospital ward setting: elaborates on hyperglycemia and patient outcomes in 
this population. 
5. Hypoglycemia: discusses its role in inpatient clinical outcomes. 
6. A1C: states the role and clinical utility of obtaining the laboratory diagnostic 
measure in the hospital setting. 
7. Discharge plan: reviews the outcomes of effective discharge planning for patients 
with chronic care needs. 
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8. Role of the advanced practice nurse: discusses the important role of the nurse 
practitioner in various settings, especially in chronic care management of the 
hospitalized patient with diabetes. 
9. Conceptual framework: depicts the relationship of the provider BG management on 
the patient outcomes 
10. Summary: recaps the all the important points in this chapter leading to the methods 
and statistics chapter. 
Introduction 
Diabetes is the most common co-morbid condition for patients admitted in the 
hospital setting. In over a period of 18 years, there was a remarkable increase in hospital 
stays of patient with diabetes from 2.8 million in 1990 to 7.7 million in 2008 (Fraze, Jiang, 
& Burgess, 2010). Prior to the turn of the 21st century, inpatient hyperglycemia was poorly 
managed or ignored. The use of sliding scale insulin (SSI) was prevalent despite severe 
criticisms by diabetologists against its use. There is insufficient evidence on its benefits of 
SSI therapy in the inpatient setting (Queale, Seidler, & Bracanti, 1997). There were only a 
small number of studies focusing on inpatient glycemic management prior to the release of 
the Leuven I study in 2001 (Van Den Berghe et al., 2001). This landmark study changed the 
course of inpatient glycemic management heading into the 21st century. 
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Critical Care Setting 
The Leuven I was a prospective, randomized, controlled study conducted in Belgium. 
The investigators examined 1,548 cardiovascular post-operative patients in the surgical 
intensive care setting. The patients were given insulin therapy to manage their BGs. A total 
of 783 patients were assigned to conventional therapy with a mean BG goal of 180 mg/dl to 
200 mg/dl. The other group of 765 patients was intensively controlled to a mean BG goal of 
80 mg/dl to 110 mg/dl. Results were favorable in the intensively treated group with 
decreased intensive care unit (ICU) mortality by 34%, sepsis by 46%, dialysis by 41%, 
blood transfusion by 50%, and polyneuropathy by 44% (Van Den Berghe et al., 2001). 
Following the tremendous success of the Leuven I study, Van den Berghe and 
colleagues (2006) conducted the Leuven II study. This prospective, randomized, controlled 
study of 1,200 medical intensive care (MICU) patients investigated the reduction of 
morbidity and mortality with intensive insulin therapy. The findings suggested that there 
was no overall decrease in mortality in the intensively treated group versus the control 
group. Mortality rate slightly increased in patients who received intensive insulin therapy 
who stayed in the ICU less than 3 days. However, for those intensively treated patients who 
stayed in the ICU greater than 3 days, the mortality rate decreased. Morbidity was reduced 
in the intensively treated group. Furthermore, intensive glucose control prevented new 
kidney injury, reduced the duration of mechanical ventilation, and shortened ICU stay (Van 
den Berghe et al., 2006). 
Two years after the publication of the Leuven I study, Krinsley (2003) examined 
glucose control outcomes in a mixed medical and surgical ICU in Stamford Hospital, 
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Stamford, Connecticut. Retrospective data was collected from 1,826 consecutive patients 
between October 1999 and April 2002. Patients with mean BG values between 80 mg/dl 
and 99 mg/dl had the lowest ICU mortality of 9.6%. Mortality rate progressively worsened 
with the increase in mean BG values reaching 42.5% on patients with mean BG values 
greater than 300 mg/dl (Krinsley, 2003). 
Following his 2003 publication, Krinsley (2004) assessed the effects of intensive 
glucose management using a protocol in the same heterogeneous ICU setting. A total of 800 
well-matched participants were enrolled in the study. The use of the protocol significantly 
improved mean BG levels from pre-intervention baseline to post-intervention (baseline 
group= 152.3 mg/dl to 130.7 mg/dl vs. treatment= 130.7 mg/dl to 119 mg/dl) without 
significantly increasing the risk for severe hypoglycemia less than 40 mg/dl (0.35% to 
0.34%). The number of patients with new kidney dysfunction and the need for blood 
transfusion decreased after protocol implementation. The number of hospital-acquired 
infections did not significantly change. Mortality rate decreased from 29.3% to 20.9%, and 
mean length of stay (LOS) decreased from a baseline 3.58 days to 3.19 days with treatment 
(Krinsley, 2004). 
In 2008, Krinsley presented his results on the role of glycemic variability (GV) in 
hospital mortality. This study was a retrospective review of 3,250 prospectively evaluated 
patients from October 1999 to October 2007. BG ranges were grouped into four standard 
deviation (SD) quartiles with quartile 1 having the lowest SD and quartile 4 with the 
highest SD. The study showed that GV is a strong independent predictor of mortality. The 
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lower SD quartile was associated with a lower mortality rate. As the SD quartile increased, 
mortality rate also correspondingly increased (Krinsley, 2008). 
The most current study to date was a large international multicenter study 
conducted by the NICE SUGAR study investigators in 2009. A sample size of 6,104 non-
eating patients with hyperglycemia [with or without history of diabetes) was examined. 
This is a parallel group, randomized, controlled study looking at MICU and S1CU patients in 
42 hospitals (38 academic and 4 community hospitals) in the United States, Australia, and 
New Zealand. The intensively controlled (IC) group of 3,054 patients had a mean BG goal of 
81-108 mg/dl while the control group (CG) of 3,050 patients had a mean BG goal of less 
than or equal to 180 mg/dl. The primary endpoint was death within 90 days of study 
enrollment. The secondary endpoints were survival after 90 days, cause of death, duration 
of mechanical ventilation, renal failure, 1CU stay, and hospital stay. Tertiary endpoints are 
death from any cause within 28 days, place of death (ICU or another level of care), 
incidence of new organ failure, positive blood cultures, and need for blood transfusions. 
The results were significant for intensively controlled group versus the control group as 
follows: mean BG of 107 mg/dl vs. 142 mg/dl, increased insulin use with 97.2% vs. 69%, 
increased mortality with 27.5% vs. 24.9%, 1CU mortality of 62.9% vs. 66.3%, and increased 
risk of severe hypoglycemia <40 mg/dl with 6.8% vs. 0.5%, respectively. It is important to 
note that a major limitation of this study is that a substantial portion of the intensively 
treated patients in the study did not achieve target BG goal (NICE SUGAR Investigators, 
2009). 
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Surgical Care Setting 
In Portland, Oregon, Furnary and his colleagues (2003) evaluated 3,554 post 
coronary artery bypass surgery (CABG) patients from 1987 to 2001. Patients where placed 
on subcutaneous insulin and patients from 1992 to 2001 were on continuous insulin 
infusion (CII) for aggressive hyperglycemia management. The results from this 
observational study indicated that mortality rate was lower for insulin infusion (2.5%) 
compared to subcutaneous insulin (5.3%). Furthermore, perioperative glycemic control 
using continuous insulin infusion on the day of surgery through post-operative day two 
showed an absolute mortality rate of 57% in the diabetes population. 
Furnary and Wu (2006) released findings on coronary artery bypass graft (CABG) 
patients - an ongoing prospective, nonrandomized, interventional study of 5,534 patients 
with diabetes who were placed on CII for 3 days (on the day of surgery through post­
operative day two). Associations of various outcomes to levels of hyperglycemia were 
found including: (1) inpatient mortality rate increased corresponding to increases in BG 
levels with a marked increase at BGs > 250 mg/dl; (2) deep sternal wound infection (DSWl) 
rates sharply increased at BG levels > 175 mg/dl; (3) length of stay (LOS) gradually 
increased corresponding to incremental increases in BG levels: and, (4) inpatient 
complications, i.e., blood transfusions, new onset atrial fibrillation, any type of infection, 
low cardiac output syndrome, prolonged ventilation, pneumonia, and cerebrovascular 
accidents correlated to increases in BG levels. Tight glycemic control for the first 3 days 
post-surgery effectively reduced BGs to near normal levels, reduced mortality rate by 65%, 
DSWl by 63%, and LOS by 2 days. Based on the results of this study, Furnary and his 
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associates advocated tightening BG control on the first 3 days post-CABG, also known as 3-
BG (Furnary & Wu, 2006). 
Some studies were also conducted on noncardiac surgical patients to evaluate 
glucose control outcomes for this population. Umpierrez and his colleagues (2011) 
examined 211 patients who were randomly assigned to two treatment groups: basal-bolus 
insulin regimen (n=104), and sliding scale regimen (n=107). The purpose of the study was 
to evaluate optimal treatment of hyperglycemia for this population to prevent poor 
outcomes. Since these patients did not require an ICU stay, subcutaneous insulin regimen 
was the treatment of choice. The study showed that the patients who were placed on basal-
bolus insulin regimen had improved glycemic control and reduced complications compared 
to the patients on sliding scale insulin regimen. 
Frisch and colleagues (2010) conducted a retrospective study at Emory University 
Hospital in Atlanta, GA on 3,184 patient medical records. The patients in the sample had 
any of the following surgeries: general, neurosurgery, oncology, orthopedic, vascular, 
thoracic, urology, otolaryngology, and gynecology. The objective of the study was to 
determine the impact of perioperative hyperglycemia on clinical outcomes such as, LOS, 
complications, and mortality. Overall 30-day mortality was 2.3% significantly higher in 
patients with higher BG levels before and after surgery, than patients with lower BG levels. 
Perioperative hyperglycemia was associated with longer hospital and ICU LOS, with higher 
incidences of postoperative pneumonia, systemic blood infections, urinary tract infections, 
and acute myocardial infections. In a multivariate analysis adjusted for age, gender, 
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ethnicity, and severity of surgery, mortality risk increased in proportion to perioperative 
BG levels in patients with no prior history of diabetes. 
General Hospital Ward Setting 
Hyperglycemia is not unique in the 1CU setting yet majority of the earlier studies 
conducted since Leuven I in 2001 and other studies through 2004 were primarily on 
critical care patients. In 2002, Umpierrez and his associates published their retrospective 
study on hyperglycemia as a marker for inpatient mortality in the general inpatient (ICU 
and non-ICU) population. They evaluated 2,030 consecutive adult patients with 
hyperglycemia (with or without prior history of diabetes) in Georgia Baptist Medical 
Center in Atlanta, Georgia. The study period was from July 1,1998 to October 20,1998. The 
primary endpoint was death. The secondary endpoints were treatment of hyperglycemia, 
LOS, and disposition at discharge. Hyperglycemia was defined as a fasting BG >126 mg/dl 
or a random BG > 200 mg/dl twice during the hospital stay. Results showed that 
hyperglycemia was present in 38% of the total hospital population (26% with history of 
diabetes and 12% with no prior history of diabetes). New hyperglycemia was associated 
with increase in mortality rate of 16% vs. 3% on patients with history of diabetes. New 
hyperglycemia was also associated with increased LOS and admission to the ICU. 
Furthermore, hyperglycemia was also associated with decreased likelihood of patients 
being discharged to home and increased transfer to transitional care units or long-term 
care facilities. 
Umpierrez and associates (2002) showed that new hyperglycemia caused poor 
outcomes in the acute care population. The effects of admission hyperglycemia in the acute 
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care setting on patients with type 2 diabetes who were admitted into the hospital for the 
first time with pneumonia was investigated by a group of researches in Denmark in 2007. 
They retrospectively examined whether patients with type 2 diabetes had increased 
mortality and complications after pneumonia. They also wanted to know if there was any 
value of admission hyperglycemia in this cohort. 29,900 patients were admitted for the 
first time into the hospital for pneumonia between 1997 and 2004 in North Jutland and 
Aarhus counties. A total of 2,931 pneumonia patients with type 2 diabetes met study 
criteria. A regression model was applied to assess for relative risk of pneumonia, 
bacteremia, and mortality rates. The results showed that there were increased mortality 
rates among the patients with diabetes than patients with no diabetes, 19.9% vs. 15.1% 
after 30 days, and 27% vs. 21.6% after 90 days. The presence of type 2 diabetes was not 
predictive of pulmonary complications and bacteremia. This study showed that type 2 
diabetes and admission hyperglycemia are associated with pneumonia-related deaths. 
Hypoglycemia 
Hypoglycemia is not an uncommon problem in hospitals nationwide. The first 
national and emergency department-based epidemiological study reported approximately 
5 million emergency department (ED) visits over 12 years (1993-2005) that was related to 
hypoglycemia. 25% of these visits resulted in a hospital admission. This is approximately 
34 per 1000 patients who have diabetes. The rate of hypoglycemia-related visits in the ED 
did not increase over time despite increase emphasis on tight glucose control (TGC) (Ginde 
etal., 2008). 
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Tightening control of BGs can increase the risk of acute hypoglycemia. Many of the 
inpatient studies related to TGC reported incidences acute hypoglycemia. Whether acute 
hypoglycemia is a marker of poor prognosis or an independent cause of mortality is still 
inconclusive. Nevertheless, hypoglycemia management requires increased hospital 
resources; it is an unpleasant and dangerous adverse reaction from severe illness or insulin 
therapy; and, both acute and chronic hypoglycemia has been associated with increased 
mortality. 
Most notable randomized controlled trials (RCTs) and other observational studies 
reported incidences of severe hypoglycemia with BGs <40 mg/dl. The RCTs that reported 
acute hypoglycemia are the Leuven I, Leuven II, and VISEP studies. Observational studies 
targeting the ICU population were reported in the Krinsley (Stamford, CT) and Vriesendorp 
(Belgium) studies. Turchin and colleagues also published a study on hypoglycemia in 
hospitalized patients with diabetes in the general acute care setting. 
In the Leuven I study with 1,548 patients in the surgical intensive care unit, severe 
hypoglycemia with BG <40 mg/dl occurred in 5.1% (39/765) of the intensively treated 
group versus 0.8% (6/783) of the controlled group (Van den Berghe et al., 2001). In the 
Leuven II study with 1,200 patients in the medical intensive care unit, 18.7% (111/595) 
patients in the intensively treated group had severe hypoglycemia compared to 3.1% 
(19/605) of the control group (Van den Berghe et al., 2006). When the data for the Leuven I 
and II were pooled together, severe hypoglycemia occurred in 11.3% (154/1360) of 
patients in the intensively treated group and 1.8% (25/1388) of patients in the control 
group (Van den Berghe et al., 2001; 2006). 
16 
The Efficacy of Volume Substitution and Insulin Therapy in Severe Sepsis study 
(VISEP) was study conducted in Germany with 537 severe sepsis patients. It was widely 
publicized because the study was abruptly terminated due to the high incidence of 
hypoglycemia 17% (42/247) in the intensively treated group compared to 4.1% (12/290) 
in the control group (Brunkhorst et al., 2008). 
In the study done by Krinsley (2005) with 1600 patients (800 patient pre- and 800 
post glucose management protocol institution), the incidences of hypoglycemia with BG 
<40 mg/dl were 0.35% and 0.34% respectively. The findings were not significant between 
the two groups. In a subsequent retrospective study by Krinsley and Grover (2007) with 
5365 patients (2666 pre and 2699 post implementation of TGC), the incidences of severe 
hypoglycemia were 1.5% and 1.3%, respectively. 
Vriesendorp and colleagues (2006) examined the short-term consequences of 
hypoglycemia (coma, seizures and death) in the ICU. They examined 245 occurrences of 
BGs <45 mg/dl with 156 patients over a period of 2 years. The researchers found that 
seizures and coma occurred infrequently with their study population. Furthermore, they 
found no relationship between incidental hypoglycemia and mortality. However, with a 
small data set and lack of randomization, they could not fully exclude hypoglycemia having 
a causative role in mortality in patients admitted to the ICU. 
Turchin and colleagues (2009) published a retrospective study on the relationship 
of hypoglycemia with BG <50 mg/dl and clinical outcomes on patients with diabetes 
admitted to the general ward. They studied a cohort 4,368 admissions of 2,582 patients 
between January 2003 and August 2004. Hypoglycemia was observed in 7.7% of the 
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admissions. The results showed that hypoglycemia was associated with increased mortality 
during the hospital stay and 1-year from discharge. Each additional day of hypoglycemia 
was associated with an increase of 85.3% odds of death and three-fold increase odds of 
death for every lOmg/dl decrease in the lowest BG during hospitalization. LOS also 
increased by 2.5 days for each additional day with hypoglycemia. This means that inpatient 
mortality and LOS increased gradually as the number of hypoglycemic events rose. 
Glycosylated Hemoglobin A1C 
AiC assays are traditionally used in the outpatient setting to measure average blood 
glucose during the previous two to three months. AiC assays are expressed as the 
percentage of hemoglobin that is glycated. AiC assays are becoming a routine part of 
laboratory testing for patients with diabetes (Nathan, et al. 2008). Normal AiC level is 4-6%. 
An AiC of >6.5% is predictive of diabetes. Good glucose control is an AiC of <7% (ADA, 
2011). Both patients and practitioners generally have to find a conversion chart to find the 
average glucose corresponding to the AiC. Nathan and his associates (2008) examined 507 
participants with type 1 diabetes (n=268), type 2 diabetes (n=159), and patients with no 
diabetes (n=80) to determine if AiC can be accurately expressed as an average glucose 
(eAG). The linear regression equations did not differ significantly across the study sample. 
In 2009, the Internal Expert Committee on the role of the AiC assay in the diagnosis of 
diabetes recommended the routine use of AiC in the diagnosis of diabetes (The 
International Expert Committee, 2009). 
The use of AiC assay was uncommon in the inpatient setting until the last decade of 
the 20th century. AiC assays are increasingly being utilized in the inpatient setting due to 
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the increasing prevalence of hospitalized patients with diabetes and hyperglycemia with no 
prior history of diabetes. Wexler and associates (2008] examined the prevalence of 
unrecognized diabetes in 695 hospitalized adults with no history of diabetes using AiC 
assays. The study results showed that 18%, or 1 in every 5 patients admitted to the 
hospital with no history of diabetes, had an elevated AiC >6.1% (Wexler et al. 2008). 
There is ample evidence that AiC has great clinical utility in the hospital setting, 
especially in the day-to-day management of glucose control and subsequent diabetes 
discharge planning. 
Discharge Plan 
Inpatient to outpatient transfer of care is an important part of good glycemic care. 
Patients enrolled in established and well-structured outpatient diabetes care follow-up 
have better outcomes. Although the outpatient outcomes of diabetes follow-up are well 
recognized, there is little known about the transfer of care from inpatient to outpatient. 
When managing inpatients with complex diabetes care needs, it is important to link these 
patients back to outpatient care. 
Wheeler and associates (2004) reported a retrospective study of 658 inpatients of a 
municipal hospital in the heart of downtown Atlanta. A hospital-based certified diabetes 
nurse educator (CDE) saw most of the patients as an inpatient. The follow-up care was 
stratified into outpatient follow-up (69%), acute care follow-up (15%), and no follow-up 
(16%). The odds for coming to the Diabetes Clinic increased if patients were discharged 
with insulin, had new onset diabetes, or had a direct referral from the CDE. 
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Four years after the publication of Wheeler and associates' (2004) study, Cook and 
colleagues (2009) released a review article on Endocrine Practice about effective planning 
for inpatient to outpatient transfer of diabetes care. Their web search for studies related to 
diabetes discharge planning (between 1998 and 2007) yielded very few and inadequate 
results. This means there were limited studies available on diabetes discharge planning 
before Wheeler's study and thereafter. 
Discharge planning has become a national patient safety goal and priority addressed 
by the National Patient Safety Goals and the Centers for Medicare and Medicaid Services 
(Cook et al., 2009). The Joint Commission made it a national priority by setting guidelines 
and offering hospitals an option to become certified in inpatient diabetes (Joint 
Commission, 2011). Cook and associates (2009) defines effective diabetes discharge as one 
where the patient received necessary skill training while in the hospital, and provided a 
clear and understandable post-discharge plan. 
Discharge planning with diabetes nurse follow-up has been shown to improve 
patient adherence to treatment regimen and improve AiC. Wong and associates (2005) did 
a randomized prospective study in the medical department of a regional hospital in Hong 
Kong. A total of 101 patients were included in the study, 49 in the control group and 52 in 
the study group. The outcome measures were AiC, self-care adherence, health care 
utilization, and patient satisfaction. The results showed that patients in the study group had 
better AiC, higher blood glucose monitoring, higher exercise adherence, lower LOS, and 
lower overall cost. There was no difference in patient satisfaction. 
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Since inpatient glycemic management is multidimensional, a thorough glycemic 
management should include addressing both inpatient glucose control and effectively 
planning diabetes self-management for discharge. 
Advanced Nursing Practice Role in Diabetes Management 
The increased demands on both the physicians and nurses leave little time to 
address the patients' insulin requirements based on glucose variability and rapidly 
changing needs. Some of the challenges to effective inpatient glycemic management and 
discharge planning were identified from a physician's perspective and the nursing 
perspective (Cook, et al., 2009). 
From the physician's perspective, patients with preexisting diabetes may be difficult 
to manage because: (1) majority of the focus of care is on the co-morbid conditions that 
triggered the hospital admission; (2) fear of hypoglycemia causing deleterious effects; (3) 
insulin administration is only initiated at BG levels of greater than 180 mg/dl to 200 mg/dl; 
(4) inadequate adjustment of diabetes medications due to alteration in nutritional support 
and medical illness, (5) unpredictability of hospital-related procedures; and (6) 
medications can affect glucose metabolism (Cook et al., 2009; Lansang & Umpierrez, 2008). 
The nurses also face challenges similar to those faced by physicians. This includes finding 
little to no time for comprehensive diabetes education and discharge planning, in addition 
to juggling an ever increasing patient care tasks (Cook et al., 2009). 
The physician or a nurse individually, or both, may be inadequately equipped to 
handle the challenges of a comprehensive inpatient glycemic management. It requires a 
multidisciplinary team to sufficiently tackle complex disease management. Disease 
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management is a patient care service that is coordinated and comprehensive, addressing 
care across the health care delivery continuum. A review of 102 research studies showed 
that disease management programs were associated with improved outcomes such as 
patient satisfaction, patient adherence, disease control, patient knowledge, morbidity, and 
mortality (Ofman et al., 2004). Many of these disease management programs are staffed 
with registered nurses (RNs), advanced practice nurses (APNs), and other healthcare 
professionals who have specialized training or expertise in their particular field of disease 
management. It is not uncommon to find nurses in disease management teams because 
nurses have a unique insight in the patient's care needs. 
Although nursing has been around for centuries, advanced nursing practice first 
emerged in the later part of the 20th century. Despite being only half a century old, the 
nurse practitioner (NP) practice has undergone many professional, academic, and role 
changes over the last five decades. The NP role is now an integral part of the mainstream 
health care delivery system. NPs traditionally practiced in the outpatient care setting but 
the emerging demands of complex disease management and the increasing role of disease 
management teams have shifted the NPs' practice towards the inpatient setting. 
NP practice has been extensively researched in terms of the quality of care and 
patient outcomes compared to physicians. Mundinger and colleagues (2000) conducted a 
randomized controlled trial to compare the outcomes of patients assigned to NPs or 
physicians for a primary care follow-up and ongoing care after an emergency room visit. A 
total of 1316 patients were enrolled in the study; 806 randomized to NPs and 510 
randomized to physicians. No significant differences were found in patient's health status 
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at six months between the two groups. Physiologic tests results for both diabetes and 
asthma were also not different. Patients with hypertension showed lower diastolic value 
for the NP group versus the physician group. No difference was found in healthy services 
utilization and patient satisfaction at initial visit. Interestingly, physicians had higher 
patient satisfaction scores at six months. Where the NP practice is held at the same 
authority, responsibilities, productivity and administrative requirements, and have the 
same patient population as the primary care physicians, patient outcomes appear equal in 
all but one domain (Mundinger et al., 2000). 
Another study comparing patient care delivery between NPs and physicians was 
conducted in a large teaching hospital in Iowa (Pioro et al, 2001). They randomly assigned 
318 patients admitted to a general medical ward to either NPs or housestaff. The NP group 
had 193 patients and the housestaff group had 188 patients. Patient demographics were 
similar for both groups. Outcomes at discharge and six weeks thereafter were similar in 
both groups including LOS, charges, costs, consultations, complications, transfers to ICU, 
30-day mortality, patient assessments of care, changes in activities of daily living, SF-36 
scores, and symptom severity. However, 90 of the 193 patients under the NP group were 
transferred to the care of the housestaff by NP or housestaff request. Despite the change in 
sample population distribution, the care between the two groups was similar. 
NPs have also expanded their role in diabetes case management. Mullen and Kelly 
(2006) reviewed 57 patient cases that were followed by NPs who performed the diabetes 
case manager roles. The study evaluated AiC, total cholesterol (TC), and low-density 
lipoprotein (LDL), six months after discharge. Significant reductions in AiC and TC were 
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observed but no reduction in LDL was noted. This study showed that for this patient 
population, patients followed by APNs as diabetes nurse case managers had improved 
outcomes. 
NPs who are providers and case managers of diabetes care are often part of 
multidisciplinary teams. Jakoby and colleagues (2008) conducted a prospective, nine-
month study on 308 admissions, to determine the impact of a glycemic management team's 
intervention on both hospital and outpatient glycemic control. The team consisted of an 
endocrinologist, a nurse practitioner, diabetes nurse educators, and registered dietitian. As 
a team, they provided a coordinated glycemic management during the patient's hospital 
stay. BG levels improved significantly with the team's intervention (195 ± 72 mg/dl to 162 
± 41 mg/dl). AiC measures also improved with 8.2% ± 2.1% prior to admission versus 
three months after discharge with 7.3% ± 1.6%. Approximately 80% of patients agreed to 
basal-bolus therapy after discharge compared to 56.8% prior to admission. Approximately 
82.6% of patients discharged on basal-bolus insulin regimen were still on the regimen 
three months after discharge. The study supports that a team approach to patient care 
improves diabetes self-management and improve both inpatient and outpatient glycemic 
control (Jakoby et al., 2008). 
Other than NPs, clinical nurse specialists (CNS) have also taken a role in inpatient 
glycemic management teams. In an article that appeared in Clinical Nurse Specialist, Custer 
(2010) described the role of a CNS in improving glucose management in an ICU setting. The 
study evaluated glucose control of 124 patients. 64.5% (80/124) did not receive any 
treatment. 22.6% received sliding scale insulin injections other than the standardized 
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orders. 12.9% received either the standardized basal-bolus subcutaneous insulin orders 
(4% or 5/124) or insulin infusion (8.9% or 11/124). When the standardized orders were 
used correctly, the mean BG level was 175 mg/dl with a median of 149 mg/dl. When the 
standardized orders were not used correctly, the mean BG level was 206 mg/dl with a 
median of 190 mg/dl. The CNS encountered many challenges in implementing the program 
including provider's persistence with using sliding scale insulin, lack of basal insulin use, 
and inconsistent use of standardized orders. The author also noted that the CNS role was 
limited due to the lack of prescribing privileges to initiate glycemic management orders. 
Conceptual Framework 
Inpatient glycemic management has been traditionally the responsibility of the 
attending physician caring for the patient. Healthcare practices changed over the last few 
decades resulting in more complex inpatient management and increased healthcare 
provider responsibility. The mounting evidence of the benefits of improved glycemic 
control added another layer of responsibility to an already demanding physician schedule. 
Hence, GMT was implemented to provide assistance to physicians in improving glycemic 
control for hospitalized patients with diabetes or hyperglycemia. 
The main assumption of this study is that the GMT-managed patients, despite having 
more co-morbid conditions, will have improved glycemic control, decreased in-hospital 
complications, and decreased costs compared to patients managed alone by the physician. 
Hence, this study will focus on the differences in the clinical outcomes and economic costs 
between the two provider groups, as well as determine if there is a relationship between 
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the a ranges of glucose control predictor variables with various clinical and economic 
outcomes (See Figure 1). 
Figure 1. Conceptual Model 
Hospital Glycemic Management 
Conceptual Framework 





















Successful implementation of a glycemic control program in the hospital setting may 
depend on effectively addressing the barriers or obstacles to success. These obstacles are 
(1) physicians are inadequately equipped to deliver diabetes care alone; (2) tightening 
glucose control to improve patient outcomes while minimizing or avoiding severe 
hypoglycemia; and, (3) providing clear discharge plan and instructions. 
The institution of GMTs in the hospital setting hopes to address these challenges. 
The GMT provides additional resources for physicians and staff in managing patients' 
glycemic control. (2) As the resident glycemic control experts, control patients' BGs to 
glycemic targets while minimizing or avoiding severe hypoglycemia. (3) Address the 
patients' discharge needs by providing a comprehensive discharge plan. 
The GMT in this study consists of NPs and diabetes nurse educators (CDE) who are 
under the supervision of the diabetes medical director. Together, and in collaboration with 
attending physicians, pharmacists, dietitians, and nurses, they provide care for patients 
referred to the GMT. Once the patient is referred to the GMT, the NPs will assume 
responsibility in managing the patient's glucose control and diabetes discharge treatment 
modification during the hospital stay. The NPs keep similar hours as the attending 
physicians, providing coverage 24-hours a day. The diabetes nurse educators function as 
diabetes case managers along with the NPs. The diabetes nurse educators are available 
Monday through Friday to provide patients with diabetes survival skills, education, 
supplies, resources and referral to outpatient diabetes education or case management. 
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CHAPTER 3: METHODOLOGY 
Significance of the Study 
In the last decade, a plethora of the research studies showed that improved blood 
glucose control resulted in better clinical outcomes. Economic cost savings have not been 
as thoroughly investigated, but have been largely assumed. The ADA, AACE, and other 
medical organizations recommended the use of a chronic disease management team like 
the GMT; however, its use has not been thoroughly evaluated in relation to clinical 
outcomes and economic costs. 
In this era of economic downturn and increased healthcare costs amidst the new 
healthcare reform environment, limiting costs while improving outcomes are a priority. 
The results of this study can inform and guide healthcare agencies, policy makers, clinicians, 
researchers, educators, and healthcare consumers about the effects of glycemic control on 
clinical outcomes and economic costs. 
Despite the increased use of NPs in the outpatient setting, NP practice is still 
relatively uncommon in the inpatient setting. Outcomes related to inpatient glucose 
management by the GMT, where NPs primarily manage glucose control, can promote 
advanced practice nursing, direct nursing education, and stimulate further research in 
nursing science. 
The purpose of this study is to examine the key clinical outcomes and economic cost 
differences between two service delivery groups, the GMT versus traditional solo physician 
management. The main assumption of this study is that the GMT-managed patients, despite 
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having more co-morbid conditions, will have improved glycemic control, decreased in-
hospital complications, and decreased costs compared to patients managed alone by the 
physician. 
This chapter presents a review of the study aims and questions, and a description of 
the research methodology including study aims, study design, sample and sampling, 
instrumentation, data collection procedures, data analysis, and the protection of human 
subjects. 
Research Aims 
Aim 1. Characterize the study population (i.e., age, gender, ethnicity, admission 
diagnosis, admission BG, A1C level, BMI, co-morbid conditions) by type of 
care delivery. 
Aim 2. Examine the differences in glycemic control: mean BG, good glucose control 
(BG 71 - 180 mg/dl), incidences of mild to moderate hyperglycemia (BG 180 
- 299 mg/dl), severe hyperglycemia BG >300 mg/dl), mild to moderate 
hypoglycemia (BG 41-<60 mg/dl), and sever hypoglycemia (<40 mg/dl), by 
type of care delivery. 
Aim 3. Examine which glycemic control variables predict rates of clinical outcomes 
(hospital complications, LOS, inpatient mortality, and 30-day readmission). 
Aim 4. Assess the relationship of glycemic control variables with economic costs 
(overall hospital costs and direct costs). 
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Aim 5. Examine the differences in inpatient diabetes services provided by type of 
care delivery. 
Research Design 
This is a cross-sectional, retrospective, quasi-experimental research study that will 
be conducted in a 343-bed, nonprofit, urban community hospital in Southern California. 
Sample and Sampling 
The hospital admitted 3,961 and 3,953 patients with diabetes in 2008 and 2009, 
respectively. This does not include patients with hyperglycemia diagnosed during the 
hospital stay. 1,000 patient cases per year (2,000 cases for the two years) between January 
1, 2008 and December 31, 2009, will be selected randomly from the electronic database for 
manual paper chart review. A final sample size of 800 patient cases that meet all study 
criteria (see Table 1) will be reviewed. The sample will be equally distributed between the 
two groups: 400 for the GMT group and 400 for the physician group. 
Inclusion Criteria 
• Diabetes/Hyperglvcemia Diagnosis: A diagnosis of diabetes or hyperglycemia 
as a secondary diagnosis will be obtained based on descriptions by diagnosis 
related group (DRG). 
• Age: All pediatric patients, once stabilized in the emergency department 
(ED), are sent to the closest children's hospital. The hospital does not offer 
inpatient pediatric services. Hence, the sample population for this study will 
include adult patients who are 18 year old and older. 
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• Complete patient characteristics and baseline information: all patient cases 
should have complete information on age, gender, ethnicity, admission 
diagnosis, admission BG, glycosylated hemoglobin AiC (or just called, AiC), 
body mass index (BMI), and type of practitioner managing the BG (see Table 
2 for listing). 
• Length of Stay (LOS): LOS has a specific definition and parameters in terms of 
billing. Admit day starts as soon as the physician writes the order and it is 
entered into the IDX hospital system software. If the patient is admitted as an 
inpatient through the ED, admission Day 1 begins regardless of when the 
patient is transferred to the ward/unit. Cut off is at midnight for discharge. 
Discharge day is not counted as part of the admission day. For example, if 
the patient was admitted in the ED on 01.01.11 and discharged on 01.05.11, 
that would be a four-day LOS. For the purpose of this study, patient cases 
with LOS of three days or more are included. LOS less than three days will 
not provide adequate blood glucose values for analysis of the primary 
endpoints; hence, they are excluded from the data. 
• BG Values: Two or more glucose values per patient day from point-of-care 
(POC) blood glucose fingerstick and laboratory serum glucose are included to 
ensure that there is an adequate number of BGs included in the analysis. 
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Exclusion Criteria 
• LOS > 14 days: Preliminary analysis of patients with diabetes and 
hyperglycemia showed that a cut-off of 14 days includes 85% of the total 
patients. The team determined that LOS > 14 days may skew the data 
negatively. Patients with LOS >14 days stay for several reasons: they could 
have placement issues, hence they stayed in the hospital longer; they have no 
insurance, hence they stay so their treatment can be completed before 
discharge; or, they are sicker or terminally ill but their level of care requires 
hospitalization. 
• DKA/HHS Patients: Patients admitted for the primary diagnosis of diabetes 
ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) are excluded 
from the study. These patients' BGs are intentionally kept outside of the 
hospital glycemic targets and at high levels for the first 24-48 hours to allow 
for BGs to return to normal or near normal levels gradually. 
• Location: only patients admitted to all units in the acute care setting and 
critical care setting are included in the study. Patients who are in the long-
term care facilities attached to the main hospital are excluded from the study. 
Procedures 
Patient cases will be randomly sampled from the pool of patients with the use of the 
hospital patient database for the periods described. Patient cases will be selected through 
electronic query based on this study's inclusion criteria i.e., a diagnosis of either diabetes or 
hyperglycemia (BG > 180 mg/dL during the hospital stay), 18 years of age or older, stayed 
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in the hospital for 3 or more days, have available demographic & baseline data (see Table 
2), and recorded BG values of two or more in a 24-hour period. Patient cases that do not 
meet all the inclusion criteria or if admitted in diabetes crises will be eliminated from the 
analysis (see Table 1). 
Data will be obtained through electronic medical records (EMR), electronic financial 
records (EFR), and paper chart reviews (PCR). Although the hospital system uses EMR for 
some of it's patient information, documentation of clinical information is still largely 
entered on paper charts. The basal-bolus order set was implemented on February 14, 2010, 
along with the implementation of the GMT to assist in the daily management of BG control. 
The GMT only intervened with patients referred by the physician for GMT consult. The 
physicians continued to see majority of the patients with diabetes or hyperglycemia 
without the assistance of the GMT. It is therefore appropriate to evaluate the impact of GMT 
on clinical outcomes and economic costs compared to physicians on measures described on 
Table 2. 
Data Analysis 
Data will be analyzed using the SPSS 18.0.2 and Stata 11.0 programs. Descriptive 
and multivariable statistics will be used for data analysis. Descriptive statistics will be 
reported on all dependent and independent variables. 
Question 1. Is there a difference in patient characteristics between provider 
groups (GMT versus physician)? Comparison of patient characteristics 
(i.e., age, gender, ethnicity, admission diagnosis, admission BG, A1C 
level, BMI, co-morbid conditions) by practitioner types will be 
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analyzed. One-way ANOVA will be used for continuous variables to 
determine whether group means differ from each other. Categorical 
variables will be analyzed using chi-square to test for fit. 
Question 2. Is there a difference in the range of glucose control between the two 
provider groups? A Mann-Whitney U will be used to analyze glycemic 
control ordinal data between the two provider groups. Glycemic 
control predictor variables include mean BG, good glucose control (BG 
71 - 180 mg/dl), incidences of mild to moderate hyperglycemia (BG 
180 - 299 mg/dl), severe hyperglycemia BG >300 mg/dl), mild to 
moderate hypoglycemia (BG 41-<60 mg/dl), and severe hypoglycemia 
(<40 mg/dl). 
Question 3. Does level of glucose control predict rates of hospital complications, 
LOS, inpatient mortality, and 30-day readmission? Logistic regression 
will be used to determine odds ratio and describe the relationship 
between glycemic control predictor variables and rates of clinical 
outcomes (hospital complications, LOS, inpatient mortality, and 30-
day readmission). However, noting that the dependent variables are 
count data and the event occurs in a particular event or time frame, 
i.e., during the hospitalization, Poisson logistic regression or log-linear 
regression modeling may be used. 
Question 4. Which predictors account for the variance in cost of hospitalization? 
Multiple regression analysis will be employed to determine the 
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relationship of glycemic control variables with economic costs of 
overall hospital costs and direct costs. 
Question 5. Is there a difference in inpatient diabetic services (glucose 
management, diabetes education, and changes in diabetes regimen 
upon discharge by type of care delivery? These categorical variables 
will be analyzed using chi-square to test for the difference between 
the two provider groups in inpatient diabetes services provided such 
as glucose management, diabetes education and changes in diabetes 
regimen upon discharge. 
Table 6 summarizes the research aims, study questions and types of statistics 
corresponding to each research inquiry. 
Protection of Human Subjects 
Institutional Review Board approval will be obtained from the University of San Diego and 
associated health care facility. Since the data will be collected retrospectively, there will be no 
actual patient contact involving any risk. Precautions will be taken to protect patient privacy in 
accordance with the Health Insurance Portability and Accountability Act (HIPAA). Access to 
patient identifiers will be limited to data collectors (including the primary investigator, data 
analysts, accounting department personnel, and research assistants). Data will be de-identified 
prior to transferring the information to the statistician for analysis. 
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Tables 
Table 1. Exclusion & Inclusion Criteria 
• Diagnosis of Diabetes with ICD-9 codes 
250.00-250.09 and 250.30-250.99 
• Hyperglycemia with ICD-9 codes 249.00-
249.09, 249.30-249.99, and 790.29 
• Patients with complete baseline data and 
characteristics 
• Average of 3 or more days of hospital stay 
• Age 18 years & older 
• Patients with 2 or more BG values in 24 
hour period 
• Patients admitted to sub-acute and long-
term care facilities 
• Patients admitted for diabetes 
ketoacidosis or hyperosmolar 
hyperglycemic syndrome 
• LOS > 14 days 
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Table 2. Measures 
Characteristics/ • Age EMR 
Baseline data • Gender EMR 
• Ethnicity EMR 
• Admission Diagnosis EMR 
• Admission BG EMR 
• AiC EMR 
• BMI PCR 
• Practitioner managing blood glucose PCR 
Clinical • Mean BG level per patient day EMR 
Outcomes • BG w/in good control (BG 71-180 mg/dL) EMR 
• Hyperglycemia (BG > 180 mg/dL) EMR 
• Severe hyperglycemia (BG >300 mg/dL) EMR 
• Hypoglycemia (BG 41-60 mg/dL) EMR 
• Severe hypoglycemia (BG <40 mg/dL) EMR 
• Transfer to ICU EMR 
• Clinical complications (post-op wound EMR/PCR 
infections, pneumonia, respiratory failure, 
acute renal failure, and bacteremia) 
• Glucose management EMR/PCR 
• Modification of home treatment regimen based PCR 
on hospital treatment response 
• Diabetes Education PCR 
• Length of stay (LOS) EMR 
• In-hospital mortality EMR 
• 30-day readmission EMR 
Economic Costs • Overall hospital costs EFR 
• Direct costs (nursing, laboratory, & pharmacy) EFR 
1 Legend: EMR = electronic medical record; EFR = electronic financial records; PCR = paper 1 
| chart review 
44 
Table 3. Research Study Members 
Primary Investigator Crisamar Anunciado, MSN, RN, 
FNP-BC 
Inpatient Diabetes Nurse 
Practitioner; PhD 
candidate, University of 
San Diego 
Director of Nursing 
Research & Faculty, 
University of San Diego 
(USD) 





University of San Diego 
(USD) 
Kathy Shadle James, DNSc, APRN Dissertation Committee, 
Member 
Medical Director, Diabetes 
Program 
Georges M. Argoud, MD, FACE Adviser/Consultant 
Chief Executive Office Pablo Velez, PhD, RN Dissertation Committee, 
Member 
Adviser/Consultant 
Director of Research and 
Education 
Karen Wikoff, PhD, RN Adviser/Consultant 
Accountant Mark Reyes Finance Consultant 




Decision Support Staff 
Statistician Dale Glaser, PhD Statistician/Consultant 
Director, Diabetes 
Program for Sharp 
Healthcare 
Jacqui Thompson, RN, MS Adviser/Consultant 
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Table 4. Statistics and Definitions 
Term Variable Type Defini t ion  





Rate of 30-day readmission 
AiC Continuous 
ANOVA 
A glycosylated hemoglobin AiC level is an average BG level over 3 
months. This laboratory test is obtained once on admission to the 
hospital. It is a useful diagnostic test in managing the patient as an 
inpatient and when deciding what diabetes regimen to send the 
patient home with upon discharge 
Admission BG Continuous 
ANOVA 
The first BG, serum glucose or POC fingerstick, obtained upon 





Admission diagnosis is the primary diagnosis listed for the 
patient's hospital stay 
Age Continuous 
ANOVA 
Age during the hospital stay 
BMI Continuous 
ANOVA 
Body mass index (BMI) is a measure of the patient's weight in 






Complications are limited the ICD-9 Codes below. For the purpose 
of this study, this variable will be identified to describe the sample 
population. 
Postoperative wound infection - ICD-9 codes: 
• 998.59 - other post operative infection 
Pneumonia - ICD-9 codes: 
• 480. * - Viral pneumonia 
• 481. * - Pneumococcal pneumonia [streptococcus 
pneumoniae pneumonia] 
• 482. * - Other bacterial pneumonia 
• 483. * - Pneumonia due to other specified organism 
• 484. * - Pneumonia in infectious disease classified elsewhere 
• 485. * - Bronchopneumonia organism unspecified 
• 486. * - Pneumonia organism unspecified 
• 997.39 - Pneumonia (aspiration) resulting from a procedure 
Respiratory failure - ICD-9 codes: 
• 518.5 - Pulmonary insufficiency following trauma and 
surgery 
• 518.81 - Acute respiratory failure 
• 518.84 - Acute and chronic respiratory failure 
Acute renal failure - ICD-9 codes: 
• 584. * - Acute kidney failure 
• 586 - Renal failure unspecified 
• 997.5 - Renal failure (acute) specified as due to a procedure 
Bacteremia - ICD-9 codes: 
• 790.7 - Bacteremia AND one of the following 3: 
• 038.0/*-038.9 - Septicemia 
• 599.0 - Urinary tract infection site not specified 
• 999.3* - Other infection due to medical care not elsewhere 
classified 
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Term Variable Type 
& Sta t i s t ics  





Comorbid conditions are all other diagnoses listed after the 
primary admission diagnosis specifically, end-stage renal disease 
or chronic renal failure, congestive heart failure, depression, 
hypertension, and hyperlipidemia. These will be identified to help 





This data will be collected and documented on the spreadsheet as a 
(0) yes or (1) no. The diabetes nurse educator who is a member of 
the GMT usually provides diabetes education. 
Direct Costs Continuous 
ANOVA 
As estimated direct cost of care will be labeled on the spreadsheet 
as: 
(0) Total direct cost 





Ethnicity will be describe based on what is entered on the 
electronic file upon admission 
Gender Categorical 
Chi Square 
Gender will be described as: 
(0) Male 
(1) Female 




It has several categories as listed: 
(0) BG <40 mg/dl 
(1) BG 41-60 mg/dl 
(2) BG 71-180 mg/dl 
(3) BG 180-299 mg/dl 
(4) BG £300 mg/dl 





Type of treatment used: 
(0) Subcutaneous prandial only 
(1) Basal-bolus 
(2) Insulin infusion 
(3) Oral antidiabetes drugs (OADs) only 
(4) Combination of insulin and OADs 
(5) None 




This is a category of the "Glucose Control" variable. BGs 71-180 are 






This data will be collected and documented on the spreadsheet as a 
(0) Yes or (1) No. Modification to home treatment regimen will be 
collected and analyzed to observe if there is a relationship between 









This is a category of the "Glucose Control" variable. BG >180 to 299 
mg/dl are considered mild to moderate hyperglycemia and will be 








This is a category of the "Glucose Control" variable. This is a 
category of the "Glucose Control" variable. BG range of 41 to 60 
mg/dl are considered mild to moderate hypoglycemia and will be 
measured per patient per patient day 
LOS Continuous 
ANOVA 
Length of stay from 3 days onward 
Mean BG level Categorical 
Chi Square 
This is a category of the "Glucose Control" variable. Mean BG level 
will be obtained from all BGs within a 24-hour period, per patient, 
per patient day 
Mortality rate Continuous 
ANOVA 
Rate of in-hospital mortality 
Overall Costs Continuous 
ANOVA 







Practitioner managing the blood glucose could be a physician with 
any type of specialty (which will be identified) or the diabetes 
nurse practitioner (DM NP) who has been consulted by the 
attending physician to assist in the management of the patient's 
BGs during patients' hospital stay. This will be labeled on the 
spreadsheet as: 
(0) DM NP 








This is a category of the "Glucose Control" variable. BGs >300 are 
considered severe hyperglycemia and will be measured per patient 








This is a category of the "Glucose Control" variable. BGs <40 mg/dl 
are considered severe hypoglycemia and will be measured per 
patient per patient day 
Transfer to ICU Categorical 
Chi Square 
A patient admitted to the general ward transferred to the ICU at 
anytime time during the hospital stay. This will be collected and 




Table 5. Descriptive Statistics 
The following table for the one-way ANOVA includes the descriptive statistics (i.e., mean, 
SD) for each group as well as the significance test result (F, p-value), effect size (r|2) and 
confidence interval around the mean difference for each of the variables. 
GMT (IV) Physician 
cm 
F p-value Tl2 95% CI 








Practitioner managing BG 
Glucose management 
Mean BG level/patient day 
BG 71 - 180 mg/dL 
BG 180 - 299 mg/dL 
BG > 300 mg/dL 
BG 41 - <60 mg/dL 
BG £ 40 mg/dL 
Comorbid conditions 
Complications 
Transfer to 1CU 
LOS 
Mortality 







Table 6. Research Aims, Questions, & Statistics 
Aims 
Characterize the study population (i.e., age, gender, 
ethnicity, admission diagnosis, admission BG, A1C 
level, BMI, co-morbid conditions) by type of care 
delivery. 
Examine the differences in glycemic control: mean BG, 
good glucose control (BG 71 - 180 mg/dl), incidences 
of mild to moderate hyperglycemia (BG 181-299 
mg/dl), severe hyperglycemia BG 2300 mg/dl), mild to 
moderate hypoglycemia (BG 41-<60 mg/dl), and 
severe hypoglycemia (s40 mg/dl), by type if care 
delivery. 
Examine which glycemic control variables predict 
rates of clinical outcomes (hospital complications, LOS, 
inpatient mortality, and 30-day readmission). 
Assess the relationship of glycemic control variables 
with economic costs (overall hospital costs and direct 
costs). 
Examine the differences in inpatient diabetes services 
provided by type of care delivery 
*Mertler& Vannatta, 2010; Munro, 2005 
Research Question 
1. Is there a difference in patient characteristics 
between provider groups (GMT versus physician)? 
2. Is there a difference in the range of glucose control 









3. Does the level of glucose control predict the rates 
hospital complications, LOS, inpatient mortality, 
and 30-day readmission? 




i.e., Poisson regression 
modeling 
Degree of relationship* 
Multiple Regression 
5. Is there a difference in inpatient diabetes services Between group 
provided (glucose management, diabetes education differences* 
and changes in diabetes regimen upon discharge) Logistic regression 
by type of care delivery? 
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Chapter 4: MANUSCRIPTS 
MANUSCRIPT 1 
UNIVERSITY OF SAN DIEGO 
Hahn School of Nursing and Health Sciences 
Inpatient Glycemic Management: Relationship Among Glucose Control, Clinical 
Outcomes and Costs 
Crisamar Javellana-Anunciado, PhD, RN, FNP-BC 
Abstract 
TITLE: Inpatient Glycemic Management: Relationship Among Glucose Control, Clinical 
Outcomes and Costs 
AUTHORS: Crisamar J. Anunciado, PhD, RN, FNP-BC 
OBJECTIVE: The aim of this study is to examine the relationship between glycemic 
control (GC), hospital acquired complications (HAC), Charlson Comorbidity Index (CCI), 
ICU stay, length of stay (LOS), 30-day readmission (30DRA), care provider, and total 
estimated costs (TEC). 
RESEARCH DESIGN AND METHODS: A retrospective cohort study of 800 patients (n = 
400 GMT and n = 400 MD) with diabetes or hyperglycemia admitted to a large urban 
community medical center located in Southern California was conducted. Descriptive 
statistics was used for demographic and baseline data. Mann-Whitney was used to 
examine the differences in Sharp BG measures by type of care delivery. Logistic 
regression was used to estimate the likelihood of 30DRA with covariates CCI, GC, ICU 
stay, HAC, and LOS. Multiple regression analysis was used to determine the accuracy of 
the independent variables LOS, provider group, CCI, HAC, and GC in predicting TEC. 
RESULTS: GMT patients had significant higher mean BG 190 mg/dL (SD = 41) F (1, 799) 
= 4.8, p = .03, r\2= .006; and BG count 3.9 (SD = .44) F (1, 799) = 108, p = .001, y]2= .12, 
than MD patients with 183 mg/dL (SD = 43); 3.5 (SD = .44). GMT patients had higher 
A1C: 8.2, (SD = 2) F (1, 799) = 3.62, p = .057, ri2= .005 and longer LOS 5.8 days (SD = 2.5) 
F (1, 799) = 3.8, p = .053, r\2= .005 than MD patients with 7.9 SD = 2.1, 5.5 days (SD = 
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2.4]. MD patients had a statistically significant higher CCI, 1.52 (SD = 1.3) compared to 
GMT patients with 1.35 (SD = 1.2), F (1, 799) = 3.9, p = .048, r|2= .005. GMT patients had 
statistically significant higher mean days with BGs 180 - 299 mg/dL (4.8 vs. 4.2 days, p 
= .001) and BGs >300 mg/dL (1.5 vs. 1.1 days, p = .000). Comparison of BG trending per 
day over 14 days was comparable between groups except for days 1-4 when GMT 
started with higher mean BGs and days 13 and 14 of hospitalization where MD group 
trended up and GMT continued to trend down. The likelihood of 30DRA with covariates: 
CCI, GC, ICU stay, HAC, and LOS did not show significant results. Increase in LOS, GMT 
services and having 1 or more HAC were related to increase in TEC whereas increase in 
GC (>180 mg/dL) was related to decrease in TEC. 
CONCLUSIONS: GMT patients were younger; slightly more male, had higher AlC levels, 
higher mean BGs, lower CCI, higher LOS, higher TEC, and more BG count or BG checks. 
Sharp BG Measures: good glucose control (BG 70 - 180 mg/dl), hypoglycemia (BG 41-
<60 mg/dl), and severe hypoglycemia (<40 mg/dl) were comparable between groups 
except for hyperglycemia (BG 181-299 mg/dl) and severe hyperglycemia BG >300 
mg/dl), which were slightly higher for the GMT patients. Factors that might increase the 
likelihood of 30DRA such as higher CCI, GC, ICU stay, presence of HAC, and longer LOS 
were examined for association with 30DRA but showed no association. Higher 
TEC/costs were associated with longer LOS, GMT patients and presence of HAC. Higher 
in GC (>180 mg/dL) was related to decrease in costs. CCI had no significant association 
with TEC whereas LOS and HAC had significant impact on increasing TEC. Further 
studies should examine the factors e.g. inadequate discharge planning, poor patient 
compliance, lack of follow-up care, poor family/caregiver support, deterioration of 
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patient condition and medical errors increasing the LOS, 30DRA rates, and costs for 
patients with diabetes. 
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Background 
Diabetes is one of the leading comorbid conditions for hospitalized patients. 
Notably, over the past two decades, hospital stays of patient with diabetes rose from 2.8 
million in 1990 to 7.7 million in 2008 (Fraze, Jiang, & Burgess 2010). One in every five 
hospital beds is occupied by a patient with diabetes (Cook et al. 2009). The estimated 
cost of care for these inpatients is $87 billion, about half of the annual overall health 
care expenditure for diabetes (ADA 2008). Patients with diabetes, with or without 
diabetes-related comorbidity, have complex needs requiring extensive and costly 
healthcare resources (Struijs et al 2006). 
Extant studies, both observational and randomized controlled trials, indicate 
inpatient hyperglycemia, with or without a history of diabetes, results in poor patient 
outcomes (ADA 2012). An estimated one-third of patients will experience significant 
hyperglycemia during hospitalization (Levetan et al 1998). Hyperglycemia in critical 
care increases morbidity, mortality, and length of stay (LOS) and was associated with 
increased mortality and complications in the general medical/surgical units (Kornum et 
al 2007; Krinsley 2004; Umpierrez et al 2002). Intensive glucose control in surgical care 
was related with decreased mortality, sepsis, low cardiac output syndrome, blood 
transfusion, pneumonia, stroke and LOS (Frisch et al 2010; Furnary et al 2003; Furnary 
& Wu, 2006; Umpierrez et al., 2011) and decreased mortality, morbidity, sepsis, dialysis 
blood transfusion, polyneuropathy, LOS in the critical care (Krinsley 2004; Van den 
Berghe et al., 2001, 2006). 
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On the opposite end of the spectrum, 34 per 1000 hospital admissions are 
related to hypoglycemia (Ginde et al 2008). Severe hypoglycemia of BG < 40 mg/dL is 
defined in many studies although this is lower than the threshold wherein cognitive 
impairment occurs in normal individuals at BG < 50 mg/dL (ADA 2012; Schnipper et all 
2008; Umpierrez et al 2012). Hypoglycemia resulting from illness, alterations in 
nutrition, medications, and aggressive glucose control (Brunkhorst et al 2008; Moghissi 
et al., 2009; Van den Berghe et al., 2001, 2006; Vriesendorp et al., 2006) increases the 
risk for deleterious effects (e.g. seizures, coma, increased LOS) and likelihood of death 
(Turchin et al., 2009). 
Wide glucose variability (GV) including hyperglycemia and hypoglycemia are 
extremely unsafe for inpatients and are strong predictors of mortality (ADA, 2012; 
Krinsley, 2008; Moghissi et al 2009). Controlling GV can be challenging due to acute 
illness, inconsistent nutrition intake, medication changes, and timing of BG monitoring 
with insulin administration. It is important to avoid GV (BG <70 mg/dL and BG > 180 
mg /dL) by making inpatient glycemic management (IGM) an integral part of inpatient 
care (ADA 2012; Moghissi et al., 2009; Umpierrez et al., 2012). 
In the last decade, various approaches to achieving inpatient glucose control 
(IGC) were implemented at several institutions in the U.S. and abroad. However, despite 
all these efforts, IGC remains suboptimal (Boord et al., 2009). One major reason 
deterring success of IGC is its' complexity - requiring considerable effort in training and 
coordination staff and hospital resources (ADA 2012; Umpierrez et al., 2012). 
Implementation of a coordinated team approach such as a glycemic management teams 
(GMT) showed improved IGC, decreased length of stay, and improved post discharge 
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A1C levels (Flanagan et al., 2008; Jakoby et al., 2008). Agencies such as the American 
Diabetes Association (ADA), American Association of Clinical Endocrinologists (AACE), 
and the Society of Hospital Medicine (SHM) endorsed the use of team approach to IGM. 
While there is empirical support for the benefits of intensive IGM using a team 
approach, there is limited research on clinical outcomes comparing a team approach 
such as a GMT to current traditional management by physicians (MD) alone. 
The aim of this study is to examine the relationship between glycemic control 
(GC), hospital acquired complications (HAC), Charlson Comorbidity Index (CCI), ICU 
stay, length of stay (LOS), 30-day readmission (30DRA), care provider, and total 
estimated costs (TEC). 
Research Design and Methods 
A retrospective cohort design was used for this study. Participants were selected 
from patients with diabetes or hyperglycemia (N = 7914) receiving services from large 
urban community medical center located in Southern California and admitted between 
January 2008 and December 2009 to the acute and critical care settings; of these, 1000 
were randomly selected per year. Eight hundred patients met inclusion criteria: 
diagnosis of diabetes with ICD-9 codes 250.00-250.09 and 250.30-250.99; 
hyperglycemia with ICD-9 codes 249.00-249.09, 249.30-249.99, and 790.29; average of 
3 or more days of hospital stay; age 18 years & older; patients with 2 or more BG values 
in 24 hour period, and identified care provider group. Exclusion criteria were: 
admission to sub-acute and long-term care facilities; diagnoses of diabetes ketoacidosis 
or hyperosmolar hyperglycemic syndrome; and LOS > 14 days. Data for the analyses 
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were abstracted from electronic medical records and paper charts. Precautions were 
taken to protect patient privacy in accordance with the Health Insurance Portability and 
Accountability Act (HIPAA). All study procedures were reviewed and approved by 
appropriate institutional review boards and administrators. No actual patient contact 
involving any risk occurred since data was collected retrospectively. 
Measures 
The GMT and MD performed inpatient glucose management (1GM) using the 
intravenous insulin order set (IOS) in critical care (Figure 1) or the basal-bolus 
subcutaneous insulin order set (SIOS) in critical care and general medical/surgical units 
(Figure 2). Diabetes care was individualized based on the patient's unique needs 
(nutrition status, medications affecting glucose metabolism, corticosteroid use, and 
individual insulin requirements). The BG goal for SIOS was <110 mg/dL to a maximum 
of 180 mg/dL, whereas IOS goal was 80 mg/dL to 150 mg/dL. For the purpose of this 
study, Sharp BG measures were defined as severe hypoglycemia <40 mg/dL, 
hypoglycemia <60 mg/dL, good control 71 mg/dL to 180mg/dL, hyperglycemia 180 
mg/dL, and severe hyperglycemia >300 mg/dL. Glucose control (GC) was categorized 
into two levels: mean BG that achieved goal of <180mg/dL and those that did not 
achieve goal >180 mg/dL during the hospital stay. 
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Figure 1. IOS 
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Figure 2. SIOS 
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The MDs represented a variety of specialties: internists (55%, n = 220), 
hospitalists (15%, n = 60), pulmonologists (11.5%, n = 46), nephrologists (10%, n = 40), 
cardiologists (4%, n = 15), endocrinologists (1.5%, n = 6), and other (3%, n = 13). 
Although the attending MDs retained responsibility for BG management for most 
patients with hyperglycemia, they referred patients with complex insulin needs and 
difficult to control BGs to GMT for IGC. 
GMT was comprised of nurse practitioners (NP) and diabetes nurse educators 
under the supervision of the diabetes medical director and with the collaboration of 
attending physicians. Once the attending physician referred a patient to the GMT, the 
NPs assume 24-hour responsibility for IGM, which entails not only IGC but also 
assessing the need for inpatient diabetes education, reconciling diabetes medication list 
to ensure accuracy, referring to outpatient diabetes education or endocrinology follow-
up, and providing clear written instructions on diabetes treatment regimen 
modifications as needed. The diabetes nurse educator provides patients with diabetes 
survival skills, basic education, supplies (i.e. log books, handouts, glucose meter), 
resources (i.e., outpatient free clinics, support groups, classes), and referral to 
outpatient diabetes education/case management. Other measures are defined in Table 
1. 
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Table 1. Measures with Definition 
AlC Glycosylated hemoglobin is a form of hemoglobin that is measured to identify the average plasma 
glucose concentration over 120 days. Normal AlC is 4-6%. AlC of 5.7-6.4% is prediabetes. An AlC of 




Abbreviated as CCI. This was originally developed in 1984. It contained 17 categories of comorbidity, 
originally based on ICD-9-CM diagnoses and procedure codes, and their associated weights that 
provide an overall comorbidity score to reflect the cumulative increased likelihood of one-year 
mortality. The score ranges from 1-5 with increase risk of death with increase in score. The index has 
been updated in 2011 for use with ICD-10 coding. The updated weight for certain diagnoses and the 




Abbreviated as HAC. This includes postoperative wound infection, pneumonia, respiratoryfailure, 
acute renal failure and bacteremia. 
Patient 
characteristics 
Includes age, gender, race/ethnicity, admission BG, AlC, BMI, mean BG, BG count, admission diagnosis 
by medical diagnosis category (MDC), discharge disposition, Charlson comorbidity index, length of stay 
(LOS), and 30-day readmission rate. 
Sharp BG 
Measures 
In 2003, Sharp Healthcare Diabetes Initiative in San Diego, CA created the Sharp BG measures as quality 
measures for all Sharp hospitals to trend IGC. It was further refined to it's current definitions in 2009. 
The latest additions to the measures are BG <40 mg/dL and BG 70-180 mg/dL (revised from 70-199 
mg/dL). 
BG <40 mg/dl: Count of monitored days w/at least one BG <40 mg/dl 
BG <60 me/dl: Count of Monitored Days w/at least one BG <60 me/dl 
BG 70-180 mg/dl: Count of Monitored Days w/ all BGs between 70-180 mg/dl 
BG >180 me/dl: Count of Monitored Days w/at least one BG >180 mg/dl 
BG >300 mg/dl: Count of Monitored Days w/at least one BG >300 mg/dl 
Statistical Analysis 
Sample size for the analyses is 800, which is sufficient to detect a moderate 
standardized effect size (d = 0.32) using a two-tailed significance test with a power 
of .80, and a significance level of .05 (Cohen 1988). Data was analyzed using the SPSS 19 
(IBM, 2010). Descriptive and multivariate statistics was used for data analysis. 
Descriptive statistics was used for demographic and baseline data. Mann-Whitney was 
used to examine the differences in Sharp BG measures by type of care delivery. Logistic 
regression was used to estimate the likelihood of 30DRA with covariates: CC1, GC, ICU 
stay, HAC, and LOS. Multiple regression analysis was used to determine the accuracy of 
the independent variables LOS, provider group, CCI, HAC, and GC in predicting TEC. A p 
value of <0.05 was considered significant. 
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Results 
The sample was fairly evenly distributed by gender with slightly more females 
(53%, n = 422) than males. The sample was diverse with almost half Latino (48%, n = 
382), White (18%, n = 146), Asian (8%, n = 64), Black (6%, n = 44), and other (21%, n = 
164), and is representative of the city's racial breakdown as reported in the 2010 
census (US Census, 2010). Age ranged from 20 to 99 (M = 66, sd = 14.8; median = 69). 
Average body mass index (BMI) was 30.6 (sd = 8.2; median = 29), with most patients 
either overweight or obese. The most frequent diagnoses for admission were 
circulatory 26% (n = 209); respiratory system 11% (n = 89), kidney/urinary tract 
system 10.4% (n = 83), nervous system 8.5% (n = 68), and musculoskeletal/connective 
tissue 7.8% (n = 62). Patients were admitted with BG ranged from 32 mg/dL to 789 
mg/dL (M = 221, sd = 111; median = 198). Service providers were equally distributed 
(400= GMT, 400 = MD) See Table 2 for details. 
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Table 2. Patient Profile 
Overall GMT MD F(df) X'(df) P 
n = 800 n = 400 n = 400 
Age - Mean (SD) 66 (14.8) 64.5 (14.7) 67.7(14.6) 9.36 (1,798) .002 
Gender - Percent (Count) .01 
Female 53% (422) 46% (194) 53% (228) 5.79(1) 
Male 47% (388) 54.5% (206) 46% (172) 
Ethnicity - Percent (Count) 4.3 (4) .36 
Asian 8% (64) 6% (26) 9% (38) 
Black 6% (44) 5% (19) 6% (25) 
Hispanic 48% (382) 48% (192) 48% (190) 
White 18% (146) 19% (74) 18% (72) 
Other 20% (164) 22% (89) 19% (75) 
AiC - Mean (SD) 8% (2.08) 8.2% (2) 7.9% (2.1). 3.62 (1, 798) .057 
BMI - Mean (SD) 30.6 (8.3) 30.9 (8.3) 30.2 (8.3) 1.46 (1, 798) .228 
Admission BG - Mean (SD) 221 (110.8) 226 (118.4) 216(102.5) 1.77 .184 
Mean BG level (mg/dL) - Mean (SD) 186 (42) 190 (41) 183 (43) 4.8 (1, 798) .03 
Last Day BG (mg/dL) - Mean (SD) 164 (48.6) 164 (46.8) 164 (50.4) .034 (1, 798) .854 
BG Count (Lab/POC) 3.7 (.47) 3.9 (.44) 3.5 (.44) 108.6 (1,798) .000 
Medical Diagnostic Groups (MDC) - 16.37 .693 
Percent (Count) 
Circulatory System 26.1% (209) 28.8% (115) 23.5% (94) 
Respiratory System 11.1% (89) 11.5% (46) 10.8% (43) 
Kidney/Urinary tract 10.4% (83) 8.8% (35) 12% (48) 
Nervous System 8.5% (68) 9.3% (37) 7.8% (31) 
Musculoskeletal/ 7.8% (62) 7.5% (30) 8% (32) 
Connective Tissue 
Digestive System 6.9% (55) 7% (28) 6.8% (27) 
Infectious and Parasitic 6.1% (49) 5% (20) 7.3% (29) 
Endocrine, Nutritional, & 5.9% (47) 5.5% (22) 6.3% (25) 
Metabolic System 
Hepatobiliary System & Pancreas 5.6% (45) 6.5% (26) 4.8% (19) 
Skin, Subcutaneous Tissue & 5.3% (42) 3.8% (15) 6.8% (27) 
Breast 
Other 6.3% (51) 6.5% (26) 6.25% (25) 
One-way ANOVA showed GMT providers provided care to patients with a 
statistically significant higher mean BG 190 mg/dL (SD = 41) F (1,799) = 4.8, p = .03, 
r]2= .006; and BG count 3.9 (SD = .44) F (1, 799) = 108, p = .001, r\2= .12, than patients 
followed by the MD 183 mg/dL (SD = 43); 3.5 (SD = .44), respectively. There was a 
trend for GMT patients to have higher admission A1C: 8.2, (SD = 2) F (1, 799) = 3.62, p 
= .057, r|2= .005 and stay longer in the hospital at 5.8 days (SD = 2.5) F (1, 799) = 3.8, p 
= .053, ri2= .005 than those followed by MDs with 7.9 SD = 2.1, 5.5 days (SD = 2.4). MD 
64 
patients had a statistically significant higher CCI,1.52 (SD = 1.3) compared to GMT 
patients with 1.35 (SD = 1.2), F (1, 799) = 3.9, p = .048, r)2= .005. 
The institution used Sharp BG Measures to report hospital-wide BG control 
(Refer to Table 1 for details). GMT patients had statistically significant higher mean 
days with BGs 180 - 299 mg/dL (4.8 vs. 4.2 days, p = .001) and BGs £ 300 mg/dL (1.5 vs. 
1.1 days, p = .000). See Table 3 for comparison. 
Table 3. Sharp BG Measures: Glucose Control By Count of Days 
Measure Overall GMT MD F(df) n2 p value 
n = 800 n = 400 n = 400 
Good Control 71 - 180 mg/dL (SD) 1.5(2) 1.4(2) 1.6(2) 1.4 (1, 798) .002 .237 
Hyperglycemia 180 - 299 mg/dL (SD) 4.51 (2.25) 4.8 (2.3) 4.2 (2.2) 11.2 (1, 798) .014 .001 
Severe Hyperglycemia i 300 mg/dL (SD) 1.29 (1.58) 1.5(1.7) 1.1(1.4) 12.7 (1, 798) .016 .000 
Hypoglycemia 41 - 60 mg/dL (SD) .21 (0.56) .23 (0.56) .19 (.55) 1.03 (1, 798) .001 .310 
Severe Hypoglycemia S 40 mg/dL (SD) .05 (0.26) .06 (0.31) .04 (0.20) 2.28 (1, 798) .003 .131 
Comparison of BG trending per day over 14 days was almost comparable 
between groups (Figure 3) except for days 1-4 where GMT patients started with higher 
mean BGs and days 13 and 14 of hospitalization where MD patients trended up and 
GMT continued to trend down. 
Figure 3. 14-Day BG Graph Comparison 








Day 01 02 D3 04 D5 06 07 D8 09 010 Oil D12 D13 D14 
MD 208 192 186 177 173 171 164 160 160 162 160 142 126 146 
GMT 218 206 200 185 175 166 162 160 163 159 160 146 146 117 
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Chi-square analysis (Table 4) indicated associations of HAC, ICU stay, GC, and 
30DRA. One-way ANOVA evaluated differences in LOS and CCI between provider 
groups. Significant findings showed GMT patients had more BGs >180 mg/dL, longer 
LOS, higher estimated costs, and lower CCI than MD patients. 
Table 4. Associations of HAC, ICU stay, GC, CCI, LOS, and 30DRA 
Overall GMT MD X*(df) P 
n = 800 n = 400 n = 400 
Hospital-acquired Complications (yes) 5% (40) 5.5% (22) 4.5% (18) .421(1) .516 
-Percent (Count) 
ICU Stay - Percent (Count) 2.55 (2) .280 
No ICU Stay 87% (699) 87% (349) 88% (350) 
<4 days ICU Stay 11% (85) 10% (40) 11% (45) 
24 days ICU Stay 2% (16) 3% (11) 1% (5) 
Glucose control (Count) 6.85 (1) .009 
BGs <180 mg/dL 49% (393) 44% (178) 54% (215) 
BGs 2180 mg/dL 51% (407) 56% (222) 46% (185) 
30-day Readmission (yes) - Percent (Count) 16% (130) 18% (73) 14% (57) 2.35(1) .125 
Charlson Comorbidity Index (2011) 1.43 (1.2) 1.35(1.2) 1.52(1.2) .048 
- Mean (SD) 
LOS - Mean (SD) 5.67 (2.45) 5.8(2.5) 5.5 (2.4) 0.53 
Estimated Costs ($) (SD) 8334.45 8863.15 7805.75 .005 
(5393.86) (6021.35) (4630.68) 
Logistic regression was used to estimate the likelihood of 30DRA with 
covariates: CCI, GC, ICU stay, HAC, and LOS. As shown in Table 5 the overall predictive 
model for 30DRA was statistically significant (likelihood ratio chi-square = 12.343 (5), p 
= .030). Hosmer-Lemeshow test indicated the model was a good fit for the data x2 = 
9.68 (8), .288. The classification result indicated high success wherein it classified 84% 
of the cases. The overall effect size was small with Nagelkerke R square of .026. None of 
the predictor variables were significantly related to the likelihood of 30DRA. 
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Table 5. Logistic Regression Results Predicting the Probability of 30-day Readmission (n = 800) 
Predictor B Wald df Odds 
Ratio 
95% Confidence Interval P 
Lower Upper 
Charlson Comorbidity Index .126 2.98 1 1.14 .98 1.31 .085 
Glucose Control .133 .46 1 1.14 .78 1.68 .497 
ICU Stay .254 1.34 1 1.29 .84 1.98 .248 
Hospital-acquired Complication -.287 .52 1 .75 .34 1.64 .472 
Length of Stay .069 2.99 1 1.07 .99 1.16 .084 
Percent correctly classified = 84% 
Nagelkerke R2 = .026 
Simultaneous multiple regression was used to determine the accuracy of the 
independent variables LOS, provider group, CCI, HAC, and GC in predicting TEC. This 
standard multiple regression strategy was appropriate because all independent 
variables are viewed as having equal importance, there were no apriori hypotheses, and 
regression diagnostic procedures did not detect problems with multicollinearity among 
the predictor variables. All tolerance values were < 0.99. Regression results indicate 
the overall model accounts for 53% of the variance and significantly predicts TEC: R2 = 
.529, R2adj = -527, F (5,794) =178.69, p = .000. A summary of the regression coefficients 
in Table 6 indicates four of the five variables significantly contributed to the model. 
Increase in LOS, GMT services and having 1 or more HAC were related to increase in 
TEC whereas increase in GC (>180 mg/dL) was related to decrease in TEC. 
Table 6. Results of LOS, Provider Group, CCI, HAC, GC, and 30DRA in Predicting TEC (n = 800) 
Variable B B t p-value 
LOS .066 .694 27.43 .000 
GC -.024 -.053 -2.14 .032 
CCI .002 .013 .509 .611 
Provider Group .024 .052 2.11 .035 
HAC .086 .081 3.28 .001 
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Discussion 
This study examined the relationship between GC, HAC, CCI, 1CU stay, LOS, 
30DRA, care provider, and TEC. The findings indicate that for this study population, the 
patients seen by GMT were younger; slightly more male, higher A1C levels, higher mean 
BGs, lower CCI, higher LOS, higher TEC, and more BG count or BG checks. Sharp BG 
Measures: good glucose control (BG 70 - 180 mg/dl), hypoglycemia (BG 41-<60 mg/dl), 
and severe hypoglycemia (<40 mg/dl) were comparable between groups except for 
hyperglycemia (BG 181-299 mg/dl) and severe hyperglycemia BG >300 mg/dl), which 
were slightly higher for the GMT patients. 
Patients referred to GMT services had slightly higher admission BGs and were 
considered to have more difficult to manage BGs; hence, there were increased BG 
checks for patients under the GMT services. BG improvement was noted on both 
provider groups over 14 days (Figure 3). GMT patients started with higher BGs on days 
1-4 of admission, had similar BG improvement with MD patients on days 5-12, and 
better improvement on days 13 and 14. The graph showed that longer LOS was 
associated with lower mean BG. Longer LOS allowed the providers time to adjust 
treatment to improve BGs to goal. Interestingly, mean BG goal of <180 mg/dL was 
achieved in almost half of the overall sample. However, the graph showed this was 
achieved on day 4 by the MD group and day 5 by the GMT. By the last day of 
hospitalization, BG average for both provider groups was the same (BG = 164 mg/dL). 
GMT services referral of more difficult to manage BGs for IGC showed improved overall 
BG control during the hospital stay as shown in this study and the study by Jakoby and 
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associates (2008). GMT services also provided diabetes discharge planning, treatment 
modification, and education, which consequently allowed more time for MDs to focus 
their efforts in managing the patients overall care. 
30DRA rates are particularly important to most hospital institutions due to 
Medicare/Medical reimbursement guidelines that limit payment to hospitals with 
higher 30DRA rates. In 2005, it was estimated that 17.6% of hospital admissions 
resulted in a 30DRA. Older patients with chronic illnesses such as diabetes and heart 
disease tend to get readmitted to the hospital more often, however, much is still 
unknown about that factors that increase the probability of readmissions (Stone and 
Hoffman 2010). The overall 30DRA rate for this study was 16% with no significant 
difference between groups. Factors that may increase the likelihood of 30DRA such as 
higher CCI, GC, ICU stay, presence of HAC, and longer LOS were examined for 
association with 30DRA. Surprisingly, none of these variables were associated with 
30DRA. Other risk factors not evaluated in this study may have increased the likelihood 
of hospital readmissions such as inadequate discharge planning, poor patient 
compliance, lack of follow-up care, poor family/caregiver support, deterioration of 
patient condition and medical errors as a few of the reasons for readmissions (Stone 
and Hoffman 2010). 
Improved IGC was associated with decrease LOS, HAC, and costs (Frisch et al 
2010; Furnary et al 2003; Furnary & Wu, 2006; Umpierrez et al., 2011; Krinsley 2004; 
Van den Berghe et al., 2001, 2006). This study population had higher TEC/costs that 
were associated with longer LOS, GMT patients and presence of HAC; whereas higher in 
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GC (>180 mg/dL) was related to decrease in costs. CCI had no significant association 
with TEC whereas LOS and HAC had significant impact on increasing TEC. Patients in 
this study with higher LOS were managed by the GMT. Analyses from this study did not 
show association of GC (<180 mg/dL) to shorter LOS and decrease costs. 
What remains inadequately answered in this study was despite the GMT patients 
being younger and had lower CCI - both factors that were supposedly associated with 
shorter LOS, they were instead associated with longer LOS and increase TEC. However, 
we have to take this study in the context that it was a retrospective design; the effect 
sizes and correlations were small, population of patients were restricted in Southern 
California region with higher Hispanic population than national average, and many 
other factors not explored in this study. Decreasing LOS, 30DRA rates and costs are of 
particular importance in the care of diabetes patients. Further studies should examine 
the factors e.g. inadequate discharge planning, poor patient compliance, lack of follow-
up care, poor family/caregiver support, deterioration of patient condition and medical 
errors increasing the LOS, 30DRA rates, and costs for patients with diabetes. 
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Abstract 
TITLE: Inpatient Glycemic Management: Team Approach in Diabetes Education and 
Discharge Planning 
AUTHORS: Crisamar J. Anunciado, PhDc, FNP-BC 
OBJECTIVE: The aim of this study was to assess the association between discharge 
planning (education, treatment modification) and care coordination by the glycemic 
management team (GMT) and physician (MD) for hospitalized diabetics. 
RESEARCH DESIGN AND METHODS: A retrospective cohort study of 800 patients (n = 
400 GMT and n = 400 MD) with diabetes or hyperglycemia admitted to a large urban 
community medical center located in Southern California was conducted. Chi-square 
analyses (categorical variables) and ANOVA (continuous variables) were used to test 
for associations in patient characteristics, inpatient diabetic services (diabetes 
education and discharge treatment modification) and provider group. For the logistic 
regression analyses, models were fit to identify factors associated with the probability 
of receiving inpatient education, treatment modification, and having a 30-day 
readmission. 
RESULTS: The sample was slightly more females 53% than males. Average age was 
66±14.8. The most frequent admission diagnoses were circulatory 26%, respiratory 
system 11%, kidney/urinary tract system 10.4%, nervous system 8.5%, and 
musculoskeletal/connective tissue 7.8%. The sample was 48% Latino, 18% White, 8% 
Asian, 6% Black and 21% other. Patient education was given to 61.6% of GMT patients 
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versus 38.4% MD patients. Diabetes treatment modification was made for 53.2% of 
GMT patients compared to 46.8% of MD patients. For patients admitted with AiC levels 
^ 8.1%, 54.9% of GMT patients received services compared to 45.1% MD patients. 
Patients who had a high admission AIC, treatment modification, and care coordinated 
by GMT were more likely to receive education. Patients who had a high admission AIC 
and received discharge education were more likely to have treatment modification. 
Patients who had a longer hospital stay were more likely to be readmitted in 30 days. 
CONCLUSIONS: Diabetes care coordinated by GMT received more patient education 
and discharge treatment modification than their MD counterparts. The GMT also 
provided more services to patients with admission AIC a 8.1%. There was no difference 
in care coordination for patients who were readmitted in 30 days. Study findings 
provide additional data for health care and policy agencies considering the use of GMTs 
in the inpatient setting to improve overall discharge planning and care coordination for 
hospitalized patients. Further research is needed to explore definitive inpatient glucose 
control, economic costs, and post discharge outcome differences between the two 
service provider groups. 
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Background 
Diabetes is the most common co-morbid diagnosis for hospitalized patients. It 
accounts for increased emergency department visits, longer lengths of stay, and higher 
cost of care than patients without diabetes (ADA, 2008; Fraze, Jiang, & Burgess, 2010). 
Notably, patients with diabetes occupy one in every five hospital beds at a staggering 
cost of $87 billion annually (Cook, et al., 2009; Moghissi, 2004). Inpatient glycemic 
management (IGM), glucose control, and establishing an appropriate discharge plan, are 
widely recognized as integral parts of inpatient care; however, wide glucose variability, 
persistent hyperglycemia, and recurrent and severe hypoglycemia are noted in many 
inpatient settings (Krinsley, 2003, 2004, 2008; Krinsley & Grover, 2007; Umpierrez et 
al., 2002). 
IGM has traditionally been the responsibility of the patient's attending physician; 
however, changes in healthcare practices over the past decade have resulted in more 
complex inpatient management. Previous research identified barriers to effective care 
for patients with preexisting diabetes: (1) care focused primarily on acute illness that 
triggered hospital admission; (2) fear of hypoglycemia causing deleterious effects; (3) 
insulin administration initiated at blood glucose (BG) levels greater than 180 mg/dL to 
200 mg/dL; (4) inadequate adjustment of insulin in response to changes in nutrition 
status and medical illness; (5) unpredictability of hospital-related procedures; (6) 
medication affects on glucose metabolism; and (7) time constraints (Cook et al., 2009; 
Lansang & Umpierrez, 2008). Successful implementation of IGM depends on effectively 
addressing these barriers. 
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Healthcare administrators implemented programs targeting inpatient glycemic 
control based upon the American Diabetes Association (ADA) and the American College 
of Clinical Endocrinologists (AACE) recommended inpatient glycemic control targets: 
BG levels of 140 - 180 mg/dL in critical care and less than 140 mg/dL premeal with no 
random BG more than 180 mg/dL for acute care. Based upon the extant research on 
intensive glucose control (BG <140 mg/dL), risks for multi-organ failure, sepsis, 
morbidity, mortality, and length of stay are significantly reduced (Krinsley & Grissler, 
2005; Van den Berghe et al., 2001). These targets come with a caveat in achieving 
euglycemia - control hyperglycemia, but limit the possible deleterious consequences of 
severe hypoglycemia (ADA, 2010; Moghissi, et al., 2009). 
In response, healthcare organizations were quick to adopt various forms of 
insulin protocols with mixed successes and failures. The increased use of insulin in the 
hospital setting brought new challenges for clinicians regarding patient safety issues. 
Indeed, insulin is the number one drug implicated in medication errors causing harm 
(Hicks et al., 2008). The AACE and ADA recognized a physician or nurse singularly 
might be inadequately equipped to handle the challenges of a comprehensive IGM. In 
fact, administrative support and inpatient glycemic expert providers are needed to 
successfully monitor patient safety and manage care (Moghissi, 2004; Moghissi et al., 
2009). 
IGM is further complicated by many factors affecting inpatient glycemic control 
(IGC) (Smith et al., 2005) requiring a multidisciplinary team to sufficiently tackle 
disease management in today's complex healthcare environment. Ofman et al (2004) 
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seminal review identified disease management as a coordinated and comprehensive 
patient care service addressing care across the health care delivery continuum. Disease 
management is associated with improvement in patient satisfaction, patient adherence, 
disease control, patient knowledge and decreased morbidity and mortality. Many of 
these programs are staffed with advanced practice nurses (APNs) and other healthcare 
professionals with specialized training or expertise in their particular field of disease 
management (Custer, 2010; Wheeler et al., 2004; Wong et al., 2005). The specialized 
glycemic management team (GMT) is one team model developed to address IGM. GMTs 
are staffed with a team of healthcare professionals, which include any or all of these 
team members: physicians, APNs, diabetes nurse educators, pharmacists, and/or 
dietitians (Flanagan et al., 2008; Jakoby et al., 2008). The GMT can provide focused care 
on patients admitted with persistent hyperglycemia. These patients with high 
glycohemoglobin A1C are particularly at risk for poor short-term and long-term 
outcomes. Lack of coordinated patient care at the time of discharge to home or other 
facilities is associated with medical errors and readmission (ADA, 2012; Krinsley, 2003; 
Umpierrez et al., 2012). 
Discharge planning is designated by National Patient Safety Goals and the 
Centers for Medicare and Medicaid Services as a national patient safety priority (Cook 
et al., 2009) resulting in Joint Commission guidelines with an option for healthcare 
agencies to become certified in inpatient diabetes (Joint Commission, 2011). Effective 
diabetes discharge is one where the patient receives necessary skill training while in 
the hospital, and is provided clear and understandable post-discharge plan (Cook et al., 
2009). Previous research has found a diabetes team approach to IGM including 
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transition to ambulatory care to be effective in controlling inpatient blood glucose, 
improving post discharge A1C levels, and decreasing length of stay (Flanagan et al., 
2008; Jakoby et al., 2008) 
Although the need for IGC is well established, it is important to assess whether 
GMT's improve IGC outcomes. The aim of this study was to assess the association 
between discharge planning (education and treatment modification) and care 
coordination (GMT or MD) for hospitalized diabetics. 
Research Design and Methods 
A retrospective cohort study of patients with diabetes or hyperglycemia 
admitted to a large urban community medical center located in Southern California was 
conducted. Participants were selected from all patients with diabetes and 
hyperglycemia (N = 7914) admitted from January 1, 2008 through December 30,2009; 
of these 1000, were randomly selected per year. Eight hundred (400 GMT; 400 MD) 
met inclusion criteria (Table 1). Data for the analyses reported here were abstracted 
from electronic medical records and paper charts. All study procedures were reviewed 
and approved by appropriate institutional review boards and administrators. Since the 
data were collected retrospectively, there was no actual patient contact that involved 
any risk. Precautions were taken to protect patient privacy in accordance with the 
Health Insurance Portability and Accountability Act (HIPAA); data were de-identified 
prior to transferring the information to the statistician for analysis. 
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Table 1. Exclusion & Inclusion Criteria 
Inclusion Exclusion 
• Diagnosis of Diabetes with ICD-9 codes « Patients admitted to sub-acute and long-term 
250.00-250.09 and 250.30-250.99 care facilities 
• Hyperglycemia with ICD-9 codes 249.00- • Patients admitted for diabetes ketoacidosis or 
249.09, 249.30-249.99, and 790.29 hyperosmolar hyperglycemic syndrome 
• Patients with complete baseline data and • LOS >14 days 
characteristics 
• Average of 3 or more days of hospital stay 
• Age 18 years & older 
• Patients with 2 or more BG values in 24 hour 
period 
Measures 
Care coordination was measured by whether attending physician (MD) or GMT 
coordinated diabetes care management. The MDs represented a variety of specialties: 
internists (55%, n = 220), hospitalists (15%, n = 60), pulmonologists (11.5%, n = 46), 
nephrologists (10%, n = 40), cardiologists (4%, n = 15), endocrinologists (1.5%, n = 6), 
and other (3%, n = 13). GMT was comprised of nurse practitioners (NP), diabetic nurse 
educator, diabetes medical director, and attending physician. Once the attending 
physician referred a patient to the GMT, the NPs assume 24-hour responsibility for IGM 
that entails not only IGC, but also assessing the need for inpatient diabetes education, 
reconciling diabetes medication list to ensure accuracy, referring to outpatient diabetes 
education or endocrinology follow-up, and providing clear written instructions on 
diabetes treatment regimen modifications as needed. The diabetes nurse educator 
provides patients with diabetes survival skills, basic education, supplies (i.e. log books, 
handouts, glucose meter), resources (i.e., outpatient free clinics, support groups, 
classes), and referral to outpatient diabetes education/case management. For 
definitions of other measures, see Table 2. 
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Table 2. Measures wit n Definition 
A1C Glycosylated hemoglobin is a form of hemoglobin that is measured to 
identify the average plasma glucose concentration over -120 days. Normal 
A1C is 4-6%. However, an A1C of 5.7-6.4% is a diagnosis of prediabetes. 
An A1C of >6.5% is a diagnosis of diabetes (ADA, 2012). 
TX Modification Performed by GMT or MD based on the patient's A1C level and changing 
needs (patient's time and skill level in diabetes self-management, home 
tapering of glucocorticoids, new kidney failure, pot-operative cardiac surgery, 
and availability of environmental/support services). 
Education Performed by the certified diabetes educator who is a member of the GMT. 
Diabetes education includes providing the patient diabetes survival skills, 
basic education, supplies, outpatient resources, and referral to outpatient 
diabetes education/case management. 
Charlson Comorbidity 
Index 
This was originally developed in 1984. It contained 17 categories of 
comorbidity, originally based on ICD-9-CM diagnoses and procedure codes, 
and their associated weights that provide an overall comorbidity score to 
reflect the cumulative increased likelihood of one-year mortality. The score 
ranges from 1-5 with increase risk of death with increase in score. The index 
has been updated in 2011 for use with ICD-10 coding. The updated weight 
for certain diagnoses and the categories narrowed down to 12 comorbidities 
(Quan, et al., 2011). 
LOS Length of Stay 
30-day readmission Yes/No variable 
Patient characteristics Includes age, gender, race/ethnicity, admission BG, A1C, BMI, mean BG, 
BG count, admission diagnosis by medical diagnosis category, discharge 
disposition, Charlson comorbidity index, and length of stay. 
Statistical Analysis 
Sample size for the analyses is 800, which is sufficient to detect a moderate 
standardized effect size (d = 0.32) using a two-tail significance test with a power of .80, 
and a significance level of .05 (Cohen, 1988). Descriptive and multivariate statistics 
were used for analyses. Chi-square analyses (categorical variables) and ANOVA 
(continuous variables) were used to test for associations in patient characteristics, 
inpatient diabetic services (diabetes education and changes in diabetes regimen upon 
discharge) and provider group (GMT versus MD). For the logistic regression analyses, 
models were fit to identify factors associated with the probability of receiving inpatient 
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education, treatment modification, and having a 30-day readmission. Statistical 
analyses were performed using SPSS 19 (IBM, 2010). 
Results 
The sample was fairly evenly distributed by gender with slightly more females 
(53%, n = 422) than males. Age ranged from 20 to 99 (M = 66, SD = 14.8; median = 69). 
Patients were admitted for a variety of reasons. The most frequent medical diagnoses 
were circulatory 26% (n = 209), respiratory system 11% (n = 89), kidney/urinary tract 
system 10.4% (n = 83), nervous system 8.5% (n = 68), and musculoskeletal/connective 
tissue 7.8% (n = 62). The sample was diverse with almost half Latino (48%, n = 382), 
White (18%, n = 146), Asian (8%, n = 64), Black (6%, n = 44), and other (21%, n = 164), 
and is representative of the city's racial breakdown as reported in the 2010 census (US 
Census, 2010). See Table 3 for details. 
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Table 3. Patient Profile 
Overall GMT MD F(df)  )P(df)  P 
n = 800 n = 400 n = 400 
Age - Mean (SD) 66 (14.8) 64.5 (14.7) 67.7 (14.6) 9.36 (1,798) .002 
Gender - Percent (Count) .01 
Female 53% (422) 46% (194) 53% (228) 5.79(1) 
Male 47% (388) 54.5% (206) 46% (172) 
Ethnicity - Percent (Count) 4.3 (4) .36 
Asian 8% (64) 6% (26) 9% (38) 
Black 6% (44) 5% (19) 6% (25) 
Hispanic 48% (382) 48% (192) 48% (190) 
White 18% (146) 19% (74) 18% (72) 
Other 20% (164) 22% (89) 19% (75) 
AiC - Mean (SD) 8% (2.08) 8.2% (2) 7.9% (2.1). 3.62 (1,798) .057 
BM1 - Mean (SD) 30.6 (8.3) 30.9 (8.3) 30.2 (8.3) 1.46 (1,798) .228 
Admission BG - Mean (SD) 221 (110.8) 226(118.4) 216(102.5) 1.77 .184 
Mean BG level (mg/dL) - Mean 186 (42) 190 (41) 183 (43) 4.8 (1, 798) .03 
(SD) 
Last Day BG (mg/dL) - Mean 164 (48.6) 164 (46.8) 164 (50.4) .034 (1, 798) .854 
(SD) 
BG Count (Lab/POC) 3.7 (.47) 3.9 (.44) 3.5 (.44) 108.6 (1,798) .000 
Medical Diagnostic Groups (MDC) 16.37 .693 
Percent (Count) 
Circulatory System 26.1% (209) 28.8% (115) 23.5% (94) 
Respiratory System 11.1% (89) 11.5% (46) 10.8% (43) 
Kidney/Urinary tract 10.4% (83) 8.8% (35) 12% (48) 
Nervous System 8.5% (68) 9.3% (37) 7.8% (31) 
Musculoskeletal/ 7.8% (62) 7.5% (30) 8% (32) 
Connective Tissue 
Digestive System 6.9% (55) 7% (28) 6.8% (27) 
Infectious and Parasitic 6.1% (49) 5% (20) 7.3% (29) 
Endocrine, Nutritional, & 5.9% (47) 5.5% (22) 6.3% (25) 
Metabolic System 
Hepatobiliary System & 5.6% (45) 6.5% (26) 4.8% (19) 
Pancreas 
Skin, Subcutaneous Tissue & 5.3% (42) 3.8% (15) 6.8% (27) 
Breast 
Other 6.3% (51) 6.5% (26) 6.25% (25) 
Charlson Comorbidity Index 1.43 (1.2) 1.35 (1.2) 1.52(1.2) 3.92 (1,798) .048 
(2011) - Mean (SD) 
LOS - Mean (SD) 5.67 (2.45) 5.8 (2.5) 5.5 (2.4) 3.76 .53 
Chi-square analysis (Table 4) indicated associations between care coordinator 
and provision of education wherein 61.6% (n = 237) of GMT patients received patient 
education compared to 38.4% (n = 148) of MD patients, x2 (1) = 38.7 p = .000. Diabetes 
treatment modification was made for slightly more than half of the total patient 
population (51.9%, n = 425). Of those, 53.2% (n = 226) of GMT patients received 
treatment modification compared to 46.8% (n = 199) of MD patients, x2 (1) = 3.7 p 
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= .056. For patients admitted with AiC levels a 8.1%, slightly more than half (54.9%, n = 
174) received GMT services, and 45.1% (n = 143) received MD services, x2 (1) = 5.02 p 
= .025. Of the 130 patients readmitted within 30 days, slightly more than half, 56.2 %(n 
= 73) received GMT services, 43.8% (n = 53) received MD services, x2 (1) = 2.35 p = .125 
Table 4. Patient Education, Treatment Modification, Discharge Disposition, 30-day Readmission and 
Inpatient Care Coordination 
Overall GMT MD X*(df) P 
N = 800 n = 400 n = 400 
Treatment Modification (yes) 53% (424) 53% (225) 47% (199) 3.39(1) .006 
Education (yes) 48% (384) 61.5% (236) 38.5% (142) 38.78(1) .000 
Discharge Disposition -
Percent (Count) 
4.2 (4) .377 
Mortality 1% (8) .7% (3) 1.2% (5) 
Home 75.8% (606) 77.5% (310) 74% (296) 
Nursing home 19.8% (158) 17.5% (70) 22% (88) 
Rehab facility 1.4% (11) 1.75% (7) 1 % (4) 
Other 2% (17) 2.5% (10) 1.75% (7) 
30 day Readmission (yes) 16% (130) 18% (73) 14% (57) 2.35(1) .125 
Logistic regression was used to estimate the probability of having had discharge 
education, treatment modification, and a 30-day readmission. Predictor variables: LOS, 
care coordination, AIC, treatment modification, and education were used in the analysis 
with simultaneous entry of predictors. 
As shown in Table 5, the overall predictive model for discharge education was 
statistically significant with a likelihood ratio chi-square = 66.15 (5), p = .000. Hosmer-
Lemeshow test indicated the model was a good fit to the data x2 = 9.07 (8), .33. 
Although the overall model and 5 predictors were statistically significant, the 
classification result indicated moderate success as it only classified 62.1% of the cases. 
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The overall effect size was also modest with Nagelkerke R square .103. Three predictor 
variables were significantly related to the likelihood of receiving discharge education. 
Wald statistics indicated admission AlC, treatment modification, and care coordination 
was significant in predicting the likelihood of discharge education. Patients who had a 
high admission AlC, treatment modification, and care coordinated by GMT were more 
likely to receive education. 
Table 5. Logistic Regression Results Predicting t he pro bability o Receiving Education (N = 800) 
Predictor B Wald df Odds 95% Confidence Interval P 
Ratio Lower Upper 
Length of Stay .018 .355 1 1.01 .959 1.08 .551 
Charlson-2011 .020 .108 1 1.02 .907 1.14 .743 
A1C - admission .132 12.48 1 1.14 1.06 1.22 .000 
Provider 0 = MD; 1 = GMT) .856 33.31 1 2.35 1.76 3.14 .000 
Treatment Modification (1= yes) .475 10.15 1 1.60 1.20 2.15 .001 
Model (likelihood ratio) chi-square = 66.15 (5), p = .000 
Percent correctly classified = 62.1% 
Nagelkerke R2 =106 
The overall predictive model for treatment modification (Table 6) was 
statistically significant with a likelihood ratio chi-square = 32.93 (5), p = .000. Hosmer-
Lemeshow test indicated the model was a good fit to the data x2 = 10.15 (8), .25. 
Although the overall model and 5 predictors were statistically significant, the 
classification result indicated moderate success as it only classified 59.3% of the cases. 
The overall effect size was also modest with Nagelkerke R square .05. Two predictor 
variables were significantly related to the likelihood of treatment modification. Wald 
statistics indicated admission AlC and discharge education were significant in 
predicting the likelihood of treatment modification. Patients who had a high admission 
AlC and received discharge education were more likely to have treatment modification. 
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Table 6. Logistic Regression Results Predicting the probability of Treatment Modification (N = 800) 
Predictor B Wald df Odds 
Ratio 
95% Confidence Interval P 
Lower Upper 
Length of Stay -.025 .716 1 .97 .91 1.03 .398 
Charlson-2011 .033 .320 1 1.03 .92 1.16 .572 
A1C - admission .139 13.77 1 1.15 1.06 1.23 .000 
Provider 0 = MD; 1 = GMT) .138 .862 1 1.14 .858 1.53 .353 
Education (1=yes) 476 10.19 1 1.61 1.20 2.15 .001 
Model (likelihood ratio) chi-square = 33.93 (5), p = .000 
Percent correctly classified = 59.3% 
Nagelkerke R2 = .055 
The overall predictive model for 30-day readmission (Table 7] was statistically 
significant with a likelihood ratio chi-square = 13.98 (6), p = .03. Hosmer-Lemeshow 
test indicated the model was a good fit to the data x2 = 7.11 (8), .52. The classification 
result classified 83.8% of the cases correctly. The overall effect size was modest with 
Nagelkerke R square .03. One predictor variable was significantly related to the 
likelihood of 30-day readmission. Wald statistics indicated length of hospitalization 
significantly in predicted the likelihood of 30-day readmission. Patients who had a 
longer hospital stay were more likely to be readmitted in 30 days. 
Table 7. Logistic Regression Results Predicting the probability of 30-day Readmission (N = 800) 
Predictor B Wald df Odds 
Ratio 
95% Confidence Interval P 
Lower Upper 
Length of Stay .08 4.60 1 1.08 1.00 1.16 .03 
Charlson-2011 .12 2.79 1 1.13 .979 1.30 .09 
A1C - admission - .05  1.09 1 .948 0.85 1.04 .29 
Provider 0 = MD; 1 = GMT) .31 2.44 1 1.36 .92 2.03 .11 
Education (1=yes) .006 .001 1 1.00 .679 1.49 .98 
Treatment Modification -.155 .617 1 .85 .58 1.26 .43 
Model (likelihood ratio) chi-square = 13.98 (6), p = .03 
Percent correctly classified = 83.8% 
Nagelkerke R2 = .03 
Discussion 
The findings indicate that for the overall sample population, diabetes care 
coordinated by GMT received more patient education and only slight more discharge 
treatment modification than their MD counterparts. GMT provided more services to 
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patients with admission AlC ;> 8.1%. However, there was no difference in care 
coordination for patients who were readmitted within 30 days. Characteristics of 
patients referred for GMT services are: higher AlC, history of poor compliance with 
diabetes regimen, complex diabetes regimen (multi-dose insulin injections, insulin 
pumps, pregnant diabetics, steroid taper, major life changes due to acute illness), and 
have complex social and environmental issues (lack of family support, placement issues, 
homelessness). 
The GMT coordinates the complex care needs of these patients by working 
closely with the diabetes educator in providing specific/advanced education. They also 
collaborate with patient/family and other healthcare professionals (i.e., attending MD, 
primary care MD, diabetologists, case management, pharmacy, nutrition, social, and 
other services) in providing safe and effective discharge plan and treatment 
modification. Care coordination takes time and effort so when the patient is readmitted 
within 30 days, it is evident further targeted interventions are needed. Behavior change 
is difficult in learning new habits and thus discharge follow-up using telemedicine in 
concert with home visitation may be indicated. 
Significant findings were noted on the increased probability of having discharge 
education, treatment modification, and a 30-day readmission. There was an increased 
likelihood of patients receiving diabetes education when they had high AlC, treatment 
modification, and care coordinated by GMT. Interestingly, the likelihood of patients 
receiving treatment modification was higher when they had high AlC and received 
diabetes education regardless of care coordination. These findings may be related to 
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GMT daily routine and responsibilities. Everyday, the GMT (NPs and diabetes 
educators) reviews the list of all inpatients with glycemic issues (hyperglycemia or 
hypoglycemia) and high A1C results, and briefly meets to address needs of patients 
with complex needs. Previous studies found improvement in A1C and discharge 
planning process that indicated similar roles for the NPs and diabetes educators 
(Jakoby et al., 2008; Mullen & Kelly, 2006). 
Although diabetes education is not exclusive to the patients under the care of the 
NPs, they have easy access to diabetes educators (housed in the same office) when the 
need arise. Otherwise, MDs and nurses access diabetes educators by telephone. Unlike 
NPs, diabetes educator intervention does not require MD orders, hence, any patient 
with high A1C or is being discharged will be prioritized for education intervention. 
Diabetes educators may trigger a call to the MD if they judge the patient needs care 
coordination by the NPs for IGC or discharge treatment modification. 
Lastly, findings indicate that there is increased likelihood of readmission within 
30-days when the patient had longer LOS. This may be associated with several factors, 
i.e., more comorbid conditions, higher Charlson scores, compliance issues, living 
situations, and other social/environmental factors. 
These findings must be interpreted in the light there are several limitations to 
this study: the retrospective design, largely Hispanic population (not representative of 
the national ethnicity population distribution), and lack of outcomes post discharge. 
Regardless, taken in this context, study findings are encouraging and provide additional 
data for health care and policy agencies considering the use of GMTs in the inpatient 
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setting to improve overall discharge planning and care coordination for hospitalized 
patients. Further research is needed to explore definitive IGC, economic costs, and post 
discharge outcome differences between the two service provider groups. 
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Introduction 
Glycemic control is recognized as an important part of inpatient care due to the 
common, serious, and costly complications of poor glycemic control. Hyperglycemia, 
severe hyperglycemia, mild hypoglycemia, severe hypoglycemia, and wide glucose 
variability are implicated in poor outcomes (Krinsley 2003, 2008; Krinsley & Grover 
2007). As the incidence of diabetes continuous to become more prevalent nationwide, 
the number of hospital discharges with diabetes also increased. Hospital care costs for 
patients with diabetes are staggering - accounting for approximately $87 billion 
annually (American Diabetes Association 2008). Evidence suggests that hyperglycemia 
during acute medical or surgical illness is a marker of poor clinical outcomes with 
increased morbidity, mortality, and length of stay (Krinsley 2004; Umpierrez 2002). 
When blood glucose is intensively controlled to near normal levels, it reduces the risks 
of multi-organ failure, sepsis, morbidity, mortality, and length of stay (Krinsley & 
Grissler 2005; Van den Berghe 2001). Optimum glycemic control reduces hospital costs 
and is important to patients with acute and critical illness. Despite controversy over 
specific glycemic targets, an understanding of glycemic control is widely understood to 
be at least under a blood glucose level of 180 mg/dl (American Diabetes Association 
2010; Moghissi 2009; NICE-SUGAR 2009). Over the last decade, various approaches to 
achieving glycemic control have been implemented at several institutions nationwide 
but glycemic control remains suboptimal (Boord, 2009). There is still a considerable 
gap in research on the relationship between clinical outcomes and economic costs of 
good glycemic control. 
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Research Aims 
This retrospective research study is designed to evaluate the clinical outcomes 
and economic costs of implementing an inpatient glycemic management program 
intended to eliminate the use of the traditional sliding scale insulin (SSI] therapy in 
favor of the use of a more physiologic approach to hyperglycemia using basal-bolus 
insulin (BBI) therapy. This study will evaluate the clinical outcomes and economic costs 
of SSI vs. BBI therapy. 
The primary outcomes are to evaluate the differences in glycemic control i.e., 
mean blood glucose (BG) control, incidences of hyperglycemia (BG >180 mg/dL), severe 
hyperglycemia (BG >300 mg/dL), hypoglycemia (BG <60 mg/dL), and severe 
hypoglycemia (BG <40 mg/dL) between treatment groups (SSI vs. BBI therapy). 
Secondary outcomes include differences between treatment groups in length of stay, 
inpatient mortality, 30-day readmission rates, and economic costs, i.e., inpatient 
diabetes-related pharmacy and medical costs. 
Research Questions 
1. What are the clinical outcome differences (i.e. mean blood control, incidence of 
hyperglycemia and hypoglycemia, length of stay, inpatient mortality, and 30-day 
readmission rates) in converting from SSI therapy to BBI therapy? 
2. What are the economic cost differences (i.e. inpatient diabetes-related pharmacy 
and medical costs) in converting from SSI therapy to BBI therapy? 
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Research Design and Methods 
This is a retrospective quasi-experimental quantitative research study done at 
Sharp Chula Vista Medical Center (SCVMC), a 343-bed nonprofit community hospital in 
Southern California. A sample size of 5,000 patient cases will be reviewed 
retrospectively. This study includes historical evaluation of 1,000 patient cases per 12-
month period from March 2003 to February 2007, and another 1,000 patient cases for 
more current data comparison from the period of March 2009 to February 2010 (see 
Table 1 for details). 
Table 1. Sampling 
SSI = March 2003 to February 2005 2,000 
BBI = March 2005 to February 2007 2,000 
March 2009 to February 2010 1,000 
The patient cases will be obtained through convenience sampling with the use of 
the hospital admission database for the period described in Table 1. Patient cases will 
be selected based on this study's inclusion criteria, i.e., a diagnosis of either diabetes or 
hyperglycemia (BG > 180 mg/dL during the hospital stay), 18 years of age or older, 
available demographic & baseline data (see Table 3), recorded BG values of two or more 
in a 24-hour period, and was on either SSI or BBI therapy. Patient cases that do not 
meet all the inclusion criteria or was admitted in diabetes crises will be eliminated from 
the study (see Table 2). 
Descriptive statistics will be used describe the characteristics of the sample. 
One-way ANOVA will be applied to statistically examine this quasi-experimental 
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research study for (g = 2 groups) between-group comparisons on key outcomes (e.g., 
LOS, Mean BG, etc.). If the outcomes are logically/statistically clustered, multivariate 
approaches, such as MANOVA, will be performed. Moreover, given a host of 
demographic/baseline data and clinically relevant drivers, a predictive approach will 
also be employed. A multiple regression approach will also be utilized to ascertain 
which variables are the strongest predictors of key outcomes. 
Table 2. Exclusion & Inclusion Criteria 
Diagnosis of Diabetes or hyperglycemia Patients on sulfonylureas with insulin and/or 
oral antidiabetic medications only 
Age 18 years & older < 18 year old 
Average of 3 or more days of hospital stay < 3 day hospital stay 
Patients with all required demographic & 
baseline data 
Patient with incomplete 
demographic/baseline data 
Patients with 2 or more BG values in 24 hour 
period 
Patients with < 2 BG values in 24 hour period 
Patients on subcutaneous insulin SSI or BBI Treatment of basal insulin without short-
acting insulin 
Patients admitted for DKA or HHS 
Legend: DKA = diabetes ketoacidosis; HHS = hyperosmolar hyperglycemic syndrome 
Data will be obtained through electronic medical records (EMR) and electronic 
financial records (EFR). Hospital data from consecutive months of March 2003 to 
February 2007 will provide two years of sufficient data for SSI therapy and two years of 
BBI therapy. Additionally, hospital data from consecutive months of March 2009 to 
February 2010 will provide outcomes of the most recent year post-BBI implementation. 
Table 3 lists the three categories of measures, which were collected for statistical 
analyses: (a) demographic or baseline data (i.e., age, gender, ethnicity, admission 
diagnosis, and admission BG); (b) clinical outcome measures (i.e., mean BG level per 
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patient day, BG in good control, mild hyperglycemia, severe hyperglycemia, mild 
hypoglycemia, severe hypoglycemia, discharge diagnosis, transfer to ICU, length of stay, 
and 30-day readmission rate; and, (c) economic costs (i.e., overall hospital costs, 
inpatient pharmacy costs, and medical costs). 
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BG w/in good control (BG 71-180 mg/dL) 
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Legend: EMR = electronic medical record; EFR = electronic financial records 
In 2002, Sharp Healthcare system started collecting all BG results from both 
laboratory and point-of-care fingerstick BGs using the Roche Inform® meter from all 
five Sharp Healthcare facilities. SCVMC has more than 250 diabetes patient cases and 
more than 10,000 BG results monthly, which is the highest among the five hospitals. All 
BG results are uploaded into the system database. Upon initial review of the BG data, we 
discovered that the data became more consistent at the end of the first quarter of 2003. 
The basal-bolus protocol, called Subcutaneous Insulin Order Set (SIOS) (shown in 
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Figure 1) as well as a glycemic management team (GMT), was implemented on 
February 14, 2005. The use of SIOS increased beginning March 2005, and reached more 
than 80% use by June 2005. For the purpose of this study, hospital BG data for the 
consecutive months of March 2003 to February 2005 provides two years of data for SSI 
therapy, and the consecutive months from March 2005 to February 2007 provides the 
initial two years of BBI therapy. Hospital data for the consecutive months of March 
2009 to February 2010 provides outcomes for the most recent year post-BBI 
implementation. 
Limitations 
It is important to note that the GMT was implemented at the same time the use 
of the SIOS was implemented. The GMT is a group of nurse practitioners and diabetes 
educators under the general supervision of the diabetes medical director. When the 
patient's attending physician refers a patient to the GMT, the GMT takes over the 
diabetes care of the patient during the hospital stay. The GMT makes daily insulin 
adjustments, provides diabetes education, refers the patient to outpatient diabetes 
education program, and makes changes on diabetes regimen for home based on each 
individual patient's needs. The 3,000 patient cases on BBI therapy in this study were 
managed either by the physician alone or with the assistance of the GMT. The full 
impact of the GMT intervention will not be addressed in this study. 
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Figure 1. Subcutaneous Insulin Order Set (SIOS) 
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Risks to Patients 
There are no direct patient risks involved. All data are collected retrospectively; 
hence, there will be no actual patient contact. Precautions to protect patient privacy in 
accordance to HIPAA regulations will be taken. Access to patient information will be 
limited to data collectors (i.e., primary investigator, data analysts, accounting 
department personnel, and research assistants). Data will be de-identified prior to 
transferring the information to the statistician and the study's funding agency. 
Deliverables 
Statistical analysis plan (SAP): Data collected will be entered in an excel spreadsheet to 
include all variables listed on Table 3. Data will be transferred to SPSS PASW version 
17.0 for analysis or other statistical software preferred. 
Feasibility of study: The members of this study as listed on Table 5, discussed the 
feasibility of this study. The principal investigator of this study will be primarily 
responsible for ensuring the timeliness, integrity, accuracy all data collection, analysis, 
and final report. Other members will either assist in some capacity with the data 
collection or as consultants for the study. Table 4 outlines the milestones and timelines 
for study completion. 
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Table 4. Milestones and Timelines 
Complete data collection and statistical analysis (EMR and EFR 
data) for: SSI (March 2003 to February 2005) and BBI = March 
2005 to February 2007, and March 2009 to February 2010 
90 days 
Executive Summary 120 days 
Final Report 150 days 
*Note: study days begin post contract consummation 
Capability & Competency Description 
Sharp Chula Vista Medical Center (SCVMC) has been collecting and analyzing 
data on blood glucose measures since 2002. We have dedicated resources to our 
Diabetes Program to improve the care of our patients with diabetes. In 2005, SCVMC 
instituted a glycemic management team exclusively dedicated in managing inpatient 
hyperglycemia and subsequently setting up patients' discharge plans. Table 5 lists the 
people involved in various capacities in this research project. 
Table 5. Research Study Members 
Primary Investigator Crisamar Anunciado, MSN, RN, FNP-
BC 
Inpatient Diabetes Nurse 
Practitioner 
Medical Director, Diabetes 
Program 
Georges M. Argoud, MD, FACE Adviser/Consultant 
Chief Executive Office Pablo Velez, RN, PhD Adviser/Consultant 
Director of Research and 
Education 
Karen Wikoff, RN, PhD Adviser/Consultant 
Accountant Mark Reyes Finance Consultant 




Statistician Dale Glaser, PhD Statistician/Consultant 
Director, Diabetes Program 
for Sharp Healthcare 
Jacqui Thompson, RN, MS Adviser/Consultant 
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Proposed Budget 
The proposed budget for this study is $105,000. Refer to Table 6 for itemized 
description of the budget. 
Table 6. Financial Proposal 
IRB Fee (expedited 
review) 
Once $500 $500 $500 
Research Assistant 250 hours $40.00/hour $10,000 $10,000 
Principal 
Investigator 
480 hours $100.00/hour $48,000 $48,000 
Consultants 35 hours $200.00/hour $7,000 $7,000 
Decision 160 hours $50.00/hour $8,000 $8,000 
Support/Analyst 
Finance Consultant 80 hours $100.00/hour $8,000 $8,000 
Finance Assistant 80 hours $50.00/hour $4,000 $4,000 
(pulls pharmacy-
related costs) 
Statistician 120 hours $150.00/hour $18,000 $18,000 
Miscellaneous Office 
supplies 
Paper/ink/poster/other $700 $700 $700 
Conference Costs for • Conference $450 $450 $450 
attendance; • Hotel $250 $250 $250 
presentation of 
executive summary 




The study will be completed within 150 days from the consummation of the 
contract with funding agency. Refer to Table 7 for details on proposed payment 
schedule. 
Table 7. Milestones and Payment Schedule 
Contract execution 10% $10,500 Need check cut within net 5 
days from date of invoice 
Completion of data collection and 
statistical analysis (raw data) 
40% $42,000 Standard Payment Schedule 
Executive Summary 40% $42,000 Standard Payment Schedule 
Final Report 10% $10,500 Standard Payment Schedule 
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Figure 2. Email Notification of Award of Mission 
£ Reply & Reply to All Forward Close 
Award of Mission 
Maria Kiwalle [maria.kiwalle-mcbride@sanofi-aventis.com] 
You repled on 10/19/2010 1:47 PM. 
Sent: Tuesday, October 19, 2010 9:22 AM 
To: Gisamai Anunciado 
Good day Crisamar 
In reference to the below mission, we are pleased to advise you have been selected as our supplier: 
Code sodete / Company code : sharpchula 
Code utillsateur / User code :canundado 
Mot de passe / Password : You must use the personal password entered during your last connection 
Basal Bolus 
We will be contacting you shortly with all of the necessary documentations for proceeding forward. 
If you have any questions, please do not hesitate to contact me. 
Have a good day. 
Regards, 






Crisamar Anunciado, RN, MSN, FNP-BC 
Sharp Chula Vista Mcdical Center 
751 Medical Center Court 
Chula Vista, CA 91950 
RE: IRB #101084 / Sanofi-Aventis 
Inpatient Glycemic Management; Clinical and Economic Impact of Changing from Sliding Scale Insulin to 
Basal-Bolus 
Dear Mr. Anunciado: 
The Sharp Healthcare Institutional Review Board (IRB00000920; FWA00000084) has reviewed and expeditiously 
approved your application for the above-rcferenced research activity in accordance with 45 CFR 46.110(bXl), Category 
5. Waiver of authorization is allowed in accordancc with 45 CFR 164.512(1X2). Waiver of informed conscnt is allowed 
in accordancc with 45 CFR 46.116(d)( 1-4) and 21 CFR 56.109(cXI)> This approval includes: 
• Protocol (15Sep2010) 
This action will be reported to all committee members at the October 20, 2010 meeting. 
The following site and investigators) are approved: 
Site: Chula Vista 
Principal Investigator: Crisamar Anunciado, RN, MSN, FNP-BC 
Study Coordinator: None 
Sub-investigator and Other Study Personnel: Dale G laser, PhD 
The IRB approval reference number is 101084. Please includc this reference number in all future correspondence relative 
to this research activity. 
As a reminder, it is the responsibility of the Principal Investigator to submit periodic status reports to the IRB. 
Periodic review of this research activity may be conducted via an expedited process and is scheduled for inclusion 
on the September 21,2011 IRB meeting agenda. Approval for this research activity will expire if periodic review is 
not conducted on or before October 5,2011. Please provide a completed research status report to the IRB Office 
no later than September 6,2011 to assure timely review and continuation of this research activity. 
Changes or amendments to the research activity protocol, informed consent documents, and to other research activity-related 
documents, as well as new documents, tools or advertisements to be utilized as part of this research activity, must be 
reviewed and approved by the IRB before changes are implemented. 
It is the policy of Sharp Healthcare IRB that the Principal Investigators) submit a copy of their reports, findings, or 
manuscripts to the IRB prior to publication. Sharp HcalthCare would expect that if the results of the research project 
came to publication, their role would be properly rccognized in the research. 
SHARP ORGANIZATIONS 
Sharp I IralthCare Sharp Memorial Hospital Grossmont Hospital Corporation Sharp Chula Vista Mcdical Center 
Sharp Coronado Hospital and Healthcare Center Sharp Mesa Vista Hospital Sharp Mary Birch Hospital For Women 
Sharp Vista l*acifica Hospital Sharp Mission Park Medical Centers, Sharp Rees-Steaty Medical Centers Sharp Health Clan 











W)'jr> Spectrum Gentei Boulevard San Diego, California 92123-148<> 
Thank you and please feel free to contact Caryn Burgess, IRB Administrator, at (858) 499-4836 if you have any questions. 
Sincerely, 
David Bodkin, M.D. 
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